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ABSTRACT 
 
 Angelman Syndrome (AS) is a severe neurodevelopmental disorder that affects 
1:12000 newborns.  It is characterized by mental retardation, delayed major motor and 
cognitive milestones, seizures, absence of speech and excessive laughter.  The majority 
of AS cases arise from deletions or mutations of UBE3A gene located on the 
chromosome 15q11-13. UBE3A codes for E3-ubiquitin ligase that target specific proteins 
for degradation. To date, a wide variety of Ube3a substrates has been identified.  The 
accumulation of Ube3a-dependent proteins and their effect on the multitude of signal 
transduction pathways are` considered the main cause of the AS pathology.  While the 
majority of research has been directed towards target identifications, the overall role of 
Ube3a in activity-dependent synaptic plasticity has been greatly overlooked.  The 
present work is designed to fill some of these knowledge gaps. 
 Chapter 2 is focused on the activity-dependent aspect of Ube3a expression 
following neuronal stimulation in vivo and in vitro.  We examined total Ube3a expression 
followed by KCl depolarization in neuronal primary culture. By utilizing a subcellular 
fractionation technique, we were able to determine which cellular pools are responsive to 
the depolarization. Next, a fear conditioning paradigm (FC) was used to activate neurons 
in the paternal Ube3a-YFP reporter mouse brain. This mouse model allowed us to 
resolve spatial and temporal alterations of the maternal and the paternal Ube3a in 
hippocampus and cortex followed by FC.  In accordance to KCl depolarization results, 
we observed alterations in Ube3a protein but at later time points. Furthermore, we 
investigated if the absence of activity-dependent Ube3a changes has any effect on 
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learning and memory kinase activation. We utilized KCl and FC to determine synaptic 
activity-induced ERK 1/2 phosphorylation in acute hippocampal slices and in CA1 area 
of hippocampus of wild type (Ube3a m+/p+) and Ube3a deficient mice (Ube3a m-/p+). 
We demonstrated that Ube3a loss leads to impaired activity-dependent ERK 1/2 
phosphorylation. 
 It has been established that Ube3a m-/p+ mice have a profound deficit in LTP, 
implying the importance of this ligase in excitatory synaptic transmission. The abnormal 
LTP could be partially explained by an aberrant CaMKII function, decreased activity-
dependent ERK 1/2 phosphorylation and reduced phosphatase activity. These proteins 
have also been implicated in another form of synaptic plasticity such as long-term 
depression (LTD). Chapter 3, we investigated the contribution of Ube3a to NMDAR – 
dependent and – independent LTD. Our data showed that Ube3a m-/p+ P21-30 animals 
exhibit the impairments in both forms of LTD. Next, we focused on elucidating molecular 
mechanism underlying the reduced mGluR1/5–LTD. We discovered that mGluR1/5 
kinase activation such as ERK, mTOR and p38 is not affected by Ube3a loss. In 
concordance with previous work, we detected increased Arc expression together with 
abnormal AMPAR distribution in the Ube3a m-/p+ hippocampus. Surprisingly, the 
mGluR1/5 induced GluR2 trafficking was normal. Our findings infer that elevated Arc 
levels together with the increased internalization of AMPAR may result in compromised 
basal state of the synapses leading to a more depression-like state in Ube3a m-/p+ 
mice.  
  Evidence points that loss of Ube3a produces alterations in a variety of activity–
dependent signal transduction cascades that may ultimately result in impaired synaptic 
plasticity and cognition. Similar to AS, abnormal molecular and behavioral phenotypes 
have already been observed in other mouse models of human mental retardation such 
as Fragile X Mental Retardation Syndrome (FXS). Chapter 4 is set to explore if any 
xi 
 
correlation can be found in between these neurodevelopmental disorders. Analysis of 
crude synaptoneurosomes of adult Fmr1 KO mice revealed a significant reduction in 
Ube3a protein. Additionally, a blunted translation of Ube3a in response to mGluR1/5 
stimulation was observed. However, we didn‘t find any evidence of direct interaction 
between Ube3a mRNA and Fragile X Mental Retardation Protein (FMRP). To examine if 
some of the pathology seen in Fmr1 KO mice is due to Ube3a downregulation, we 
performed a rescue experiment by increasing overall levels of Ube3a in hippocampus of 
FRMP deficient mice. An exhaustive battery of behavioral testing indicated that 
alterations of Ube3a expression impacted only associative fear conditioning. 
 In summary, the present work has attempted to answer some of the fundamental 
questions about Ube3a and its role in synaptic plasticity. We have demonstrated that 
Ube3a expression is modulated by synaptic activation and its activity-dependent 
alterations are essential for normal brain functioning. Additionally, our data suggest that 
Ube3a is not only significant for the synaptic excitation but also crucial for the synaptic 
depression. Finally, our findings indicate that the alteration of Ube3a expression may 
contribute to the cognitive phenotypes in other neurodevelopmental disorders such as 
FXS suggesting an advantage of exploring Ube3a function outside the AS research. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Preamble 
A picture of a red-haired boy holding a drawing by Geovanni Francesco Caroto 
has been a highlight of the art exhibitions throughout Europe (Figure 1 A). Scholars have 
debated the meaning of the child‘s drawing: whether the artist was imitating the 
primitivism of a childhood art or wanted to highlight the gap between our own perception 
and the others‘ is unclear. Unexpectedly, apart from the artistic value, this portrait gained 
significance in natural science where it became a ―ground zero‖ for Angelman Syndrome 
(AS) research. This piece of art once inspired Dr. Harry Angelman to publish the first 
case study of 3 unrelated young children that he observed during his medical practice in 
England (Figure 1 B). In his article ―Happy Puppet Syndrome‖ Dr. Angelman first 
described the unique characteristics of the disorder: severe developmental delay, ataxia, 
seizures and happy demeanor (Angelman 1965). His description of 6 distinctive features 
related to the impairment of the CNS (protruding tongue, seizures, etc.) and one 
behavioral trait - outbursts of laughter - is still valid for most individuals affected by this 
rare disorder. Unfortunately, Happy Puppet Syndrome, later renamed to Angelman 
Syndrome, was almost forgotten until 1980s when Dr. Magenis linked AS to defects in 
the maternal chromosome 15 (Magenis et al. 1987). Ever since, the number of scientific 
publications has been increased annually reflecting a growing interest in the scientific 
community. 
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Figure 1. A. ―Portrait of a Young Boy holding a Child's Drawing‖ (1515) by Geovanni 
Francesco Caroto (Italian, ca.1480-1555) first inspired Dr. Harry Anglelman to publish 
―Puppet‖ children‖, a case study report of three children affected by Angleman 
syndrome (B.). 
A. 
B. 
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           1.2 Clinical and neurological features of Angelman Syndrome 
             Currently, most AS researchers agree on the common neurological features that 
present in almost 100% of the AS patients: severe mental retardation, seizure, abnormal 
movement and absence of speech (Williams et al. 2006; Dagli et al. 2011). From a very 
early age, AS children fail to reach most developmental milestones: they sit unsupported 
at 12 months and walk at mean age of 4 years old. Many of them develop tremors in the 
fingers and jerky movements in addition to a slow ataxic gait and sometimes muscle 
hypotonia (Clayton-Smith and Laan 2003). All of  the neurological symptoms other than 
the behavioral phenotype are non-specific and may be present in a wide variety of 
syndromes ranging from autism spectrum disorder (ASD) to fragile X mental retardation 
(FXS). Therefore, only behavioral traits including but not limited to excessive laughter, 
fascination with water and hyperactivity serve as a hallmark for AS and are employed to 
distinguish it from other disorders of central nervous system (CNS). Evidence suggests 
that the first and foremost noticeable symptoms of an AS child is an early onset of social 
smiling that could be seen even in 1-3 months old infants. Later, subsequent giggling is 
replaced by contagious ―bursts of laughter‖, happy disposition and happy grimacing 
observed in 77% of infants (Buntinx et al. 1995).  Interestingly, paroxysms of laughter 
are still present in adulthood, but less frequently than in early age (Laan et al. 1996). It is 
worth noting that the persistent smiling doesn‘t indicate that individuals with AS are not 
capable of experiencing negative emotions such as anger, frustration and sadness. 
            Furthermore, sleep problems such as difficulties maintaining sleep, irregular 
sleep-wake cycles, inappropriate nocturnal behaviors and sleep movement disorders are 
repeatedly reported by the parents of AS individuals (Clayton‐Smith 1993; Didden et al. 
2004; Pelc et al. 2008). The abnormal sleeping patterns suggest that the development 
and/or function of thalamocortical network may be perturbed; however, more research is 
needed to make any reliable conclusions. Interestingly, sleep disturbances and shorter 
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than normal sleep duration doesn‘t affect children‘s daytime routine suggesting the 
―diminished need for sleep‖ (Clayton‐Smith 1993). Some investigators attribute  the 
abnormal sleep patterns to increased anxiety that manifests itself not only through 
frequent night wakening and sleep walking but also hyperactive and excitable behavior 
during daytime (William, 2004). Currently, behavioral modifications as well as melatonin 
treatment are prescribed to alleviate the symptoms (Zhdanova et al. 1999). 
           Seizures are present in 85% of patients and often observed within the first 36 
months of life (Clayton‐Smith 1993). The most frequent seizure types are atypical 
absences, generalized tonic-clonic, atonic or myoclonic seizers (Laan and Vein 2005). 
Three common EEG patterns are usually observed: 1) persistent generalized rhythmic 4-
6 Hz activity not influenced by eye closure; 2) rhythm delta activity of 2-3 Hz more 
evident in the anterior regions; 3) spikes and sharp waves mixed with 3-4 Hz 
components of amplitude higher than 200 μM mainly from the posterior area and 
triggered by eye closure (Viani et al. 1995). The described EEG abnormalities are 
routinely used to diagnose AS before any cytogenetic analysis is conducted (Buoni et al. 
1999).  
Despite the great expansion and availably of modern imaging technology, there 
are not many conclusive neuroimaging results that could explain some of the 
neuropathology of AS. Early studies via computed tomography (CT) scan revealed an 
abnormal scull with diffuse cortical – subcortical brain atrophy and irregular distribution 
of neurons was observed in layer III with variation in their density (Dörries et al. 1988; 
Jay et al. 1991; Kyriakides et al. 1992; Clayton-Smith and Laan 2003). Moreover, MRI 
studies indicate that an AS brain may lack a typical organization. For example, 
examination  of  the banks and branches of the Sylvian fissure of 7 AS patients  reveals 
an abnormal organization of  the supramarginal gyrus on the left manifested in increased 
convolutions and often split between the motor and somatosensory strips (Leonard et al. 
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1993).  Additionally, AS individuals display decreased/delayed myelination, decreased 
axonal density or diameter, and aberrant axonal organization (Peters et al. 2011). It 
could be concluded that despite a relatively normal appearance, AS brain may have 
small anatomical alterations. Nevertheless, more research is needed to pinpoint specific 
brain area deviations that are responsible for the overt symptomology.  
Regardless of the severity of neurological symptoms present in AS, the affected 
individuals have a relatively normal life span and some of them successfully reach 
adolescence and even old age (53-75 years old). Unfortunately, the symptomology 
doesn‘t improve with age and contrarily the physical conditions are exacerbated. For 
instance, many of the individuals develop thoracic scoliosis ,truncal hypotonia (71%) and 
finally become wheelchair-bound (39%). The majority of the adult AS population still 
exhibits an ataxic puppet-like gait, seizures and distinctive facial features that become 
more pronounced than in childhood. Even if 86% can non-verbally communicate with the 
caregivers and 85% are able to perform simple task, AS children and adults still require 
constant medical attention and homecare due to the severe mental retardation that 
doesn‘t improve with maturation (Laan et al. 1996).  
Despite precise diagnostic tests, there are no options available for managing the 
symptoms, other than seizure control. Several experimental treatments such as 
levodopa, prednisolone, folic acid and minocycline are currently being investigated as a 
potential therapeutics, but whether these treatments whether show effectiveness or not 
remains to be seen since the data are still being collected (Hulten et al. 1991; Harbord 
2001; Forrest et al. 2009). 
 
1.3 Genetic causes of Angelman Syndrome 
AS is usually diagnosed within the first few years when a child starts exhibiting 
true delays in motor and cognitive development. However, there are a few syndromes 
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such as Rett, Christenson, Mowat-Wilson and FXS that can somewhat mimic the AS 
phenotype. As a result, the diagnosis can only be determined by cytogenetic analysis of 
chromosome 15 q11-13. Currently, there are 4 genetic causes of AS which are 
associated with chromosome 15 q11-13: various de novo microdeletions (5-7Mb) (70%), 
uniparental paternal disomy (2%), defects in the imprinting center (5%) and mutations in 
UBE3A gene (5-10%) (Lossie et al. 2001; Clayton-Smith and Laan 2003; Dagli et al. 
2011). The 5th class, a fairly large subset of the population (12-15%) with clinical AS 
characteristics, has no identifiable genetic deficits related to the AS chromosomal region. 
Recently, mutations in SLC9A6 and HERC2 have been reported in latter group (Gilfillan 
et al. 2008). This discovery raised an important possibility that many genes might be 
involved in the etiology of AS. Nevertheless, until a thorough genomic analysis of the 5th 
class of patients is conducted, AS is considered a monogenetic disorder involving 
disrupted maternal Ube3a gene expression.  
 
1.4 Ube3a is a genetic locus for Angelman Syndrome 
Ube3a is one of 100-200 imprinted genes identified in humans and mice. 
Imprinting refers to an epigenetic mechanism that leads to differential gene expression 
depending on the parent-of-origin inheritance. In most cases, imprinted genes exist in 
clusters called microdomains. One such microdomain is present on the human 
chromosome 15 q11-13, homologous to the mouse chromosome 7, and is implicated in 
several neurodevelopmental disorders such as AS, Prader-Willi Syndrome and ASD. A 
high proportion of imprinted genes found in both the placenta and CNS follow a general 
rule that if a gene is imprinted in the brain, it is also silenced in other tissue. On the 
contrary, Ube3a together with NNAt and Muurl shows mainly brain-specific imprinting 
and biallelic expression in somatic cells. Specifically, in situ hybridization reveals the 
presence of monoallelic maternal Ube3a mRNA in hippocampus and Purkinje cells, 
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while biallelic Ube3a transcripts are seen in the prefrontal cortex, cortex and the 
cerebellum (Jiang et al. 1998) . Biochemical studies of Ube3a protein in the AS mouse 
model show a complete absence of maternal Ube3a protein in CNS and reduced total 
expression in other tissue (Gustin et al. 2010). Similar observations were made in 
human brain samples (Daily et al. 2012). The discrepancies between Ube3a mRNA and 
protein expressions could be explained by a brain region-specific differential regulation 
of Ube3a; however, more experimentation is needed to determine the mechanism. 
Epigenetic silencing is usually accomplished through DNA methylation, histone 
modification and long non-coding RNA. Genetic mechanisms that govern paternal 
Ube3a imprinting belong to the latter category; however, the complete process is still 
poorly understood (Lalande and Calciano 2007). The paternal gene is thought to 
express large (<600 bp) non-coding antisense RNA (Ube3a-ATS) that is initiated in the 
Prader-Willi syndrome–imprinting center (PWS-IC). Once transcribed, Ube3a-ATS 
undergoes alternative splicing and inactivates paternal Ube3a expression. There are 
several mechanisms proposed by which processed Ube3a-ATS could mediate 
epigenetic silencing: (i) transcriptional interference resulting from the simultaneous 
occupancy of RNA polymerase complexes; (ii) RNA interference induced by double-
stranded RNA formed between sense and antisense RNAs or (iii) conformational 
chromatin change that results in transcription repression (Lalande and Calciano 2007; 
Mabb et al. 2011). 
 In AS, the maternal Ube3a gene is absent or non-functioning while the paternal 
gene is intact, but dormant, making it an appealing therapeutic target. It has already 
been demonstrated that the paternal Ube3a imprinting can be reversed genetically by 
disrupting the Ube3a-ATS or pharmacologically by the administration of topoisomerase 
inhibitors (Huang et al. 2011; Meng et al. 2012). Unfortunately, both approaches cannot 
be applied to human patients due to the methodological limitation or drug toxicity. 
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Nevertheless, these studies lay a foundation for future research by providing evidence of 
reversible epigenetic repression. 
A preponderance of work suggests that the expression of Ube3a is critical for 
normal CNS functioning. In humans, the absence of the maternal Ube3a leads to AS 
while the duplication of Ube3a results in the symptoms similar to ASD (Samaco et al. 
2005; Schanen 2006). Analogously, in mice loss of maternal Ube3a expression results in 
cognitive and motor defects (Jiang et al. 1998; Miura et al. 2002). In contrast, increased 
levels of Ube3a culminate in poor social interaction, behavioral inflexibility, and anxiety 
(Nakatani et al. 2009; Smith et al. 2011). Intriguingly, Ube3a expression in the non-
mammalian systems appears to be important as well. The loss of dUbe3a protein in 
Drosophila causes abnormal locomotive behavior and circadian rhythm, and defects in 
long-term memory. Conversely, flies that overexpress dUbe3a also display locomotion 
defect in addition to decreased dendritic branching in sensory neurons in the peripheral 
nervous system (Wu et al. 2008). 
 
1.5 Ube3a codes for E3 ubiquitin ligase 
The Ube3a gene, or E6-AP, was mapped as the genetic locus for AS in 1997 
(Kishino et al. 1997; Matsuura et al. 1997). However, it was first described in the 
relationship to cervical cancer. E6-AP was discovered to be associated with E6 
oncoprotein of the human papiloma virus, resulting in increased cell proliferation and 
tumor growth through the degradation of tumor suppressor p53 (Scheffner et al. 1993). 
Ube3a encodes a 100 kDa homologous to E6-AP carboxyl terminus (HECT) E3 ligase 
that is involved in protein degradation via the ubiquitin–associated proteosome-mediated 
pathway (UPS). E3 ligases are a very diverse group of proteins that are important for the 
recognition of specific substrates and their subsequent ubiquitination within proteolytic 
system. HECT E3 ligases are characterized by a highly conserved catalytic C-terminus 
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domain that harbors an active cysteine (Cys) residue. This Cys forms a strong thioester 
bond with an ubiquitin carried by E2 ligase and transfers it to a target protein. Similarly, 
Ube3a recognizes its substrates via its N-terminal domain and tags them with Lys48-
linked ubiquitin chain that is ultimately identified by 26S proteasomes and degraded. A 
variety of Ube3a targets have been identified including but not limited to p53, Rad23, 
MMP7, E6-AP, sacsin, RhoGEF ephexin5, Arc and Rpn10 (Huibregtse et al. 1991; 
Kühne and Banks 1998; Nuber et al. 1998; Kumar et al. 1999; Greer et al. 2010; 
Margolis et al. 2010; Lee et al. 2013). Table 1 summarizes all the major Ube3a-
dependent proteins and their functions.  
The Ube3a protein is highly expressed in somatic cells as well as in neurons and 
glia (Dindot et al. 2008). It is produced in high levels in the soma and to a lesser degree 
in dendrites in both excitatory and inhibitory neurons (Wallace et al. 2012). It primarily 
resides in cytoplasmic and nuclear cellular compartments. Ube3a is subjected to the 
alternative splicing generating 3 isoforms (Iso) (Yamamoto et al. 1997). Iso2 
corresponds to the full length protein while Iso1 and Iso3 both lack 21 amino acids from 
N-terminus. Iso1 is considered to be E3-ligase deficient since it is additionally missing 87 
amino acids from the C-terminal HECT domain. Interestingly, while Iso1 and Iso2 are 
ubiquitously found throughout a cell, Iso3 is confined to the nucleus where it seems to 
have an important place for the embryonic development (Miao et al. 2013). Total levels 
of Ube3a protein fluctuate with age. All the isoforms, especially Iso3, are highly enriched 
in the embryonic brain (E15 cortex); however, the expression gradually declines when 
the brain matures. Subcellular Ube3a localization also appears to be developmentally 
determined. Immunohistological data suggests an active Ube3a trafficking from 
cytoplasm to the nucleus occurring postnatally. Specifically, Ube3a staining shows 
almost exclusive cytoplasmic localization at P0 mouse brain; however, it is mainly found 
in the nucleus by P28. Close examination of maternal and paternal Ube3a demonstrates 
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that paternal Ube3a imprinting is more relaxed in neonates. Paternal Ube3a is abundant 
in cytoplasm until P7 when its production rapidly decreased to about 5% and remains 
the same throughout the adulthood. Conversely, hippocampal stem cells and 
oligodendrocytes exhibit billelic expression in young and aged animals (Judson et al. 
2013).  
 
1.6 Murine models for Angelman Syndrome 
Several mouse models have been created to study the role of Ube3a in CNS. A 
murine Ube3a located on chromosome 7 shows similar to humans imprinting patterns; 
therefore, in vivo modeling of AS follows maternal inheritance and involves a disruption 
of maternal Ube3a gene. Paternal Ube3a deletion is often used as a study control.  
The first mouse model was generated in 1997 by knocking out 3 kb of exon 2 of 
human UBE3A (Jiang et al. 1998). The mutation resulted in a frame shift causing  null 
Ube3a expression in all brain regions (Gustin et al. 2010). This transgenic mouse model 
quickly gained favor as it nicely recapitulated hallmark clinical AS phenotypes. The 
Ube3a deficient animals (Ube3a m-/p+) displayed abnormalities in gait (increased both 
hind stride length and hind base width), motor learning and coordination (rotarod, wire 
hang and beam crossing tests) (Jiang et al. 1998; van Woerden et al. 2007; Heck et al. 
2008). These deficits are often explained by the lack of Ube3a in Purkinje cells of 
cerebellum together with increased body weight and decreased muscle tone (grip 
strength). Interestingly, a recent study reported deficits in dopamine-dependent tasks 
including but not limited to foot clasping behavior and pole and adhesive tape removal 
tests suggesting that motor deficits can also be attributed to a reduction in the number of 
dopaminergic neurons observed in the AS substantial nigra (Mulherkar and Jana 2010).  
In addition to impaired motor coordination, Ube3a deficient mice show cognitive 
dysfunction that manifests in poor performance in the hippocampal-dependent tasks 
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such as contextual fear conditioning and hidden platform water maze (Jiang et al. 1998; 
van Woerden et al. 2007). Consistent with AS patients, epilepsy in the forms of 
spontaneous and audiogenic seizures and abnormal EEG patterns are present in Ube3a 
m-/p+ animals, especially in the 129 Sv strain.   
Furthermore, this transgenic mutant exhibits several behaviors that reflect some 
of nuanced symptoms seen in the AS population. For example, it has been reported that 
Ube3a m-/p+ mice show an abnormal licking rhythms during water consumption. This 
deficit  implies the weakened cerebellar coordination between licking, breathing and 
swallowing and closely resembles difficulties in swallowing observed in 77% of AS 
individuals (Williams et al. 2006; Heck et al. 2008). However, despite the many 
similarities, the Ube3a m-/p+ mice don‘t mimic hyperactivity and increased sociability of 
AS individuals. In contrast, AS mouse show increased body weight, reduction in motor 
activity and normal social behavior (Allensworth et al. 2011). 
A second AS mouse model was engineered by replacing  parts of exon 15 and 
full exon 16 of human UBE3A gene with a β-galactosidase (LacZ) transcriptional reporter 
to inactivate the maternal Ube3a (Miura et al. 2002). In accordance with the first 
mutation model, these animals are characterized by deficits in motor and hippocampal-
dependent learning. Additional phenotypes such as sleep disturbances, elevated 
Purkinje cell firing and rhythmicity have also been detected (Chéron et al. 2005; Colas et 
al. 2005).   
While Ube3a knockouts are sufficient to study Ube3a contribution to AS, the 
mutations in Ube3a are found only approximately 15% of all AS cases. The majority of 
affected individuals carry a large ~6Mb deletion in 15 q11-13 region. Therefore, to better 
represent the diseased state, a new transgenic mouse was made by a ~1.6 Mb maternal 
deletion that disrupted not only Ube3a but also Atp10a and Gabrb3 genes (Jiang et al. 
2010). Similarly to the deletion mutants, this mouse has abnormal EEG patterns and 
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seizure phenotype. Motor and cognitive dysfunctions are also present. Increase in 
ultrasonic vocalization was found in young pups suggesting abnormal signaling or 
communication between the mother and Ube3a m-/p+ offsprings.  This discovery may 
signify a similar behavior that is often seen in AS children: a compensatory increase in 
laughter and smiling during communication with adults. Unfortunately, it is not clear what 
specific genes are involved in the abnormal ultrasonic vocalization since this paradigm 
has never been tested in the Ube3a knockout mice. 
 The contribution of the paternal Ube3a to the mouse behavior has been 
extensively studied as well. It has been established that the animals carrying either null 
mutations or large deletion on the paternal chromosome show no differences in EEG, 
seizures or general behavior compared to the wild type littermates (Jiang et al. 1998; 
Jiang et al. 2010). A single study points to a significant difference between complete 
knockout mice (Ube3a m-/p-)  and maternal Ube3a m-/p+ in licking behavior and beam 
test alluding that paternal Ube3a may play some role in cerebellum-dependent behavior 
(Heck et al. 2008).  
Finally, a Ube3a-Yellow Fluorescent Protein (YFP) reporter mouse was created 
in the laboratory of Dr. Beaudet by fusing YFP to the C-terminus of Ube3a (Dindot et al. 
2008). This Ube3a-YFP mutant is particularly useful for visualization of the cellular 
Ube3a localization and for separate examination of maternal and paternal Ube3a 
expression in primary neurons and in the intact mouse brain. Most importantly, it 
provides a valuable tool in a pharmacological quest to ―unsilence‖ paternal Ube3a. 
Primary cultures obtained from the paternal Ube3a-YFP mouse have already been 
utilized in drug discovery experiments leading to identification of topoisomerase 
inhibitors as the first molecule cable to overcome epigenetic down-regulation of a 
paternal gene (Huang et al. 2011). 
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1.7 Alteration in synaptic plasticity in Angelman Syndrome mouse model  
The ubiquitin proteolytic system (UPS) is an important component of normal 
neuronal function. Pioneer studies of long-term facilitation in Aplysia first linked UPS to 
synaptic plasticity by demonstrating that protein kinase A (PKA) is regulated by a de-
ubiquitylating enzyme (Hegde et al. 1997; Hegde and DiAntonio 2002). Significantly, 
Ube3a became the first UPS enzyme associated with normal cognitive processes in 
humans and mice.  
The observations that disruption in maternal Ube3a leads to impaired cognition 
raised an important question about Ube3a contribution to synaptic plasticity. First 
electrophysiological study of CA3-CA1 pathway in hippocampus of Ube3a deficient mice 
revealed a profound decrease in long-term potentiation (LTP) induction and 
maintenance (Jiang et al. 1998). A detailed investigation of hippocampal plasticity 
demonstrated that lack of maternal Ube3a results in both N-Methyl-D-aspartic acid 
receptor (NMDAR) - dependent and –independent LTP deficits. Interestingly the inability 
of the pyramidal neurons to maintain normal LTP expression was overcome by 
increasing slice temperature and stimulation intensity implying an abnormal increase in 
LTP induction threshold in CA1 area of AS mice. Further biochemical analysis 
uncovered that Ube3a m-/p+ have  increased Ca2+ /Calmodulin-Dependent Protein 
Kinase II (CaMKII) phosphorylation at autophosphorylated autonomously active Thr286 
and inhibitory Thr305/306 sites together with decreased protein phosphatase 1 (PP1)/ 
protein phosphatase 2 (PP2a) phosphatase activity (Weeber et al. 2003). Later, a double 
mouse mutant was created by crossing the AS mouse with a heterozygous mouse that 
carried a CaMKII Thr305 mutated site. The mutation to CaMKII prevented the inhibitory 
Thr305 phosphorylation and restored normal CaMKII activity. The Ube3a m-/p+/CamKII 
Thr305 double mutant mouse showed no motor or cognitive deficits when compared to 
Ube3a m-/p+ littermate controls (van Woerden et al. 2007). This finding suggests that 
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defective CaMKII phosphorylation and activity is important in AS etiology; however, the 
mechanism by which Ube3a modulates the kinase remains unknown. 
Conceivably, deficits in synaptic plasticity are not only confined to hippocampal 
formation; thus, similar observations have already been reported in other brain regions. 
Several publications have documented abnormal neocortical synaptic development and 
plasticity in visual cortex (layer II-IV) in young and adult Ube3a m-/p+ mice. Specifically, 
the normal developmental increase in the frequency of mature excitatory post-synaptic 
potentials (mEPSP) was not detected in the Ube3a m-/p+ P11-12 animals. Moreover, a 
bidirectional impairment of NMDA-dependent LTP and LTD was also observed. 
Interestingly, similarly to hippocampus, neocortical LTP was rescued by stronger LTP 
stimulation protocol implying analogous biochemical mechanisms that underlie the 
defective excitatory transmission in both brain regions. Surprisingly, no CaMKII changes 
were identified in juvenile cortex (Yashiro et al. 2009). In depth investigation of inhibitory 
interneurons and excitatory pyramidal cells in layers II-III of visual cortex revealed an 
excitatory/inhibitory imbalance. It appears that reduction in maternal Ube3a affects both 
inhibitory and excitatory cell firing since the diminished mEPSP and mIPSP frequencies 
were registered.  Data shows a sever reduction in inhibitory drive that lead to decrease 
in connectivity and inhibition of pyramidal cells. This phenomenon is somewhat 
rationalized by an anomalous synaptic vesicle cycling (Wallace et al. 2012).  
A great body of literature indicates that strength of synaptic transmission 
correlates with the overall state of neuronal physiology. Empirical evidence 
demonstrates that loss of Ube3a negatively impacts dendritic arborization as well as 
dendritic spine number in the hippocampus and visual cortex. The latter could be 
connected to the increased levels of Ube3a substrates, specifically Ephexin 5. Ephexin 
5, a RhoA guanine nucleotide exchange factor is involved in the suppression of 
excitatory synapse number during development. In AS, decreases in the degradation of 
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Ephexin 5 due to the loss of Ube3a function promotes greater synapse elimination 
during development leading to a reduced number of synapses in the adulthood. In 
addition to the impaired neuronal morphology, altered active and passive intrinsic 
membrane properties and increased axon initial segments (AIS) were observed in 
Ube3a m-/p+ mice. These changes could be ascribed to the elevated levels α1 subunit 
of α Na/K ATPase (α1-NaKA), the voltage-gated sodium channel NaV1.6, and the AIS 
protein ankyrin-G. Interestingly, genetic decrease of α1-NaKA protein levels through 
genetic double crosses can rescue some of the behavioral and electrophysiological AS 
phenotype leading us to believe that defective neuronal physiology underlies some of 
the abnormal AS cognition.  
 
1.8 Ube3a and activity-dependent plasticity 
One of the remarkable features of the mammalian brain is that it undergoes 
continuous experience-driven remodeling of structure, composition and number of 
synapses. Extensive research shows that general alterations in synaptic plasticity or 
accumulation of Ube3a-dependent proteins are probable causes of AS. However, a 
possibility that AS may originate from the abnormal activity-dependent signaling is a 
provoking thought. 
 Several reports challenge a long standing statute of Ube3a as a ―housekeeping 
protein‖. First, Ube3a was proposed to have an important place in experience-driven 
maturation of excitatory synapses in visual cortex. It was later shown that Ube3a 
expression was found to fluctuate in response to synaptic activity in vivo and in vitro. 
Particularly, Ube3a mRNA was elevated following glutamatergic receptor activation in 
primary cultures and in vivo following exposure to a novel environment in behaving 
animals. Subsequent identification of a novel Ube3a-interacting protein, activity 
regulated cytoskeleton associated protein (Arc) provided some explanation to why the 
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activated neurons may have to modulate Ube3a transcription. Arc is a well-studied 
immediate early gene that undergoes rapid translation within first few minutes after 
neuronal stimulation. However, the up-regulation of Arc is short-lasting and tightly 
controlled by UPS. It is not unreasonable to hypothesize that an activity–driven increase 
in Ube3a expression is one of the regulatory mechanisms to ensure that basal levels of 
Ube3a substrates including Arc are restored. Under normal conditions, alterations in Arc 
expression allow appropriate synaptic remodeling by influencing the surface α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPAR) distribution. In the case of 
AS, chronically elevated Arc promotes increase in internalized GluR1 subunit; thus, 
negatively affecting APMAR current and the number of silent synapses. It is not known if 
the activity-dependent Arc expression and AMPAR endocytosis are regulated by Ube3a. 
Further experiments are required to investigate these molecular processes during 
neuronal firing.   
In summary, it stands to reason that Ube3a may be involved in modulating 
pathways that are involved in synaptic plasticity. This may explain why earlier work 
investigating kinase alterations in the Ube3a maternal deficient mouse only revealed an 
alteration in alpha-CaMKII phosphorylation. This data was collected under basal 
condition. It is possible that more alterations in kinase phosphorylation, protein 
degradation or receptor trafficking could be discovered by applying an activity-dependent 
approach. The observation that total Ube3a expression exhibits experience-driven 
patterns brought a new angle to AS research. Unfortunately, many questions still remain 
unanswered.  
 
1.9 Ube3a and other neurological disorders 
Individuals with AS share several symptoms with other neurodevelopmental 
disorders such as Rett and Fragile X Mental Retardation Syndrome (FXS). According to  
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 Table 1.1 Neurodevelopmental disorders with high penetrance of autistic features. 
 
Angelman Syndrome Rett Syndrome Fragile X Syndrome 
HUMAN 
   Intellectual disability severe variable variable  
Communication 
speech absent loss of spoken language variable  
Social interaction/ 
activity 
excessive laughter,  
hyperactivity excessive laughter Hyperactivity, irritability 
Motor dysfunction severe 
gait abnormalities, 
loss of hand use mild 
Brain abnormality 
decrease myelination,  
abnormal brain 
architecture 
reduced volume, white 
matter impairment,  
static encephalopathy  
eosinophilic, intranuclear 
inclusions in neurons and 
astrocytes 
Seizures present present present 
Prevalence of ASD 
features 40-60% 20%-50% 18%-33% 
Prevalence 1:12000- 1:20000 1:10000 
1:4000 females; 1:8000 
males  
Genetic deficits 
Ube3a 
mutations/deletions MeCP2 mutations Fmr1 mutations 
Molecular 
mechanism Ubiquitinaltion  Transcription regulation Translation 
    
MOUSE MODEL 
   
Locomotor behavior 
hypoactivity, ataxic gate, 
decrease in motor 
learning 
hypoactivity (males) 
 decrease in motor 
learning hyperactivity 
Anxiety normal increased decreased  
Audiogenic 
seizures present present present 
Social interaction normal impaired abnormal 
Autistic behaviors absent absent inflexibility in learning 
Cognition 
poor performance in  
hippocampal-dependent 
tasks 
poor performance in  
hippocampal-dependent 
tasks 
poor performance in fear 
conditioning , radial water 
maze 
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AS diagnostic criteria only cytogenetic analysis could definitely determine true AS cases. 
The presence of impaired social interaction and communication, repetitive behavior, 
seizures and intellectual disability places AS within ASD. Interestingly, some of the 
disorders may also have an overlapping pathology. For example, the animal models of 
FXS (Fmr1 KO) and AS are characterized by the cognitive impairments, audiogenic 
seizures, abnormal synapse number and deficits in synaptic plasticity. Despite the 
various molecular defects, these conditions may converge on the same biochemical 
pathway that includes Arc. Both, Ube3a m-/p+ and Fmr1 KO have abnormally increased 
Arc levels and subsequent alteration in AMPAR endocytosis. Although, the anomalous 
Arc expression is a result of two distinct mechanisms: increased translation in Fmr1 KO 
and decreased degradation in AS, there is a chance that similar downstream of Arc 
changes could take place in both conditions. If it holds true, some of the hallmark deficits 
in synaptic transmission observed in Frm1 KO mice should also be found in Ube3a 
deficient animals. At the present moment, no data is available to support this hypothesis. 
Recently, we have reported that treatment used in FXS clinical trial showed promising 
results in AS patients. This may imply that common dysfunctions appear in both 
syndromes. In conclusion, regardless of the genetic mechanisms, many 
neurodevelopmental disorders share common pathology; thus, it is important to 
incorporate knowledge obtained from other disease models to AS research in order to 
aid an efficient exploration for potential therapeutics.  
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CHAPTER 2: ACTIVITY-DEPENDENT CHANGES IN MAPK ACTIVATION IN THE 
ANGELMAN SYNDROME MOUSE MODEL1 
 
2.1 Abstract 
Angelman Syndrome (AS) is a devastating neurological disorder caused by 
disruption of the maternal UBE3A gene. Ube3a protein is identified as an E3 ubiquitin 
ligase that shows neuron-specific imprinting. Despite extensive research evaluating the 
localization and basal expression profiles of Ube3a in mouse models, the molecular 
mechanisms whereby Ube3a deficiency results in AS is enigmatic. Using in vitro and in 
vivo systems we show dramatic changes in the expression of Ube3a following synaptic 
activation. In primary neuronal culture, neuronal depolarization was found to increase 
both nuclear and cytoplasmic Ube3a levels. Analogous up-regulation in maternal and 
paternal Ube3a expression was observed in Ube3a-YFP reporter mice following fear 
conditioning. Absence of Ube3a led to deficits in the activity-dependent ERK1/2 
phosphorylation, which may contribute to reported deficits in synaptic plasticity and 
cognitive function in AS mice. Taken together, our findings provide novel insight into the 
regulation of Ube3a by synaptic activity and its potential role in kinase regulation. 
 
2.2 Introduction 
Angelman syndrome (AS) is a neurological disorder that affects approximately 
1:12,000 children (Steffenburg et al. 1996) and is characterized by severe 
                                                          
1
 Portions of these results have been previously published (Filonova I, 2014) and are utilized with 
permission of the publisher. 
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developmental delay, cognitive disruption, absence of speech, contagiously happy 
demeanor, ataxia, and a greater propensity for seizures (Pelc et al. 2008; Dagli et al. 
2011). Absence, mutation or disruption of the maternal UBE3A allele results in a near 
complete absence of protein expression in the central nervous system (CNS). UBE3A 
encodes an E3 ubiquitin ligase (E6-AP) that shows neuron-specific paternal imprinting in 
humans and mice (Jiang et al. 1998; Gustin et al. 2010; Daily et al. 2012). Ube3a has 
few identified biochemical targets including activity-regulated cytoskeleton-associated 
protein (Arc) and Ephexin 5 (Greer et al. 2010; Margolis et al. 2010); however, Ube3a is 
likely to play multiple roles in the neuron and no single target of Ube3a fully explains the 
unique phenotype associated with the disorder.  
A recent study by Greer et al (2010) demonstrated dynamic expression of Ube3a 
during synaptic activity. Specifically, Ube3a mRNA was significantly increased in 
response to membrane depolarization or glutamate receptor activation in cultured 
primary neurons. In addition, Ube3a expression was up-regulated in the mouse brain 
during kainate-induced seizures and in response to enhanced environmental stimuli 
during the novel object exploration test (Greer et al. 2010). Stringent control of Ube3a 
expression is necessary for neuronal functioning. A prime example of this is human 
UBE3A gene dosage. Absence of UBE3A results in AS, while the interstitial duplication 
of UBE3A is associated with autism spectrum disorders (ASD) (Schanen 2006). 
Supportive observations are made in mice lacking Ube3a and those with a Ube3a 
duplication, both of which partially phenocopy aspects of AS and ASD, respectively. 
Maternal Ube3a deficient animals show impaired locomotor activity, enhanced seizure 
propensity and deficits in associative and spatial learning and memory (Jiang et al. 
1998). Conversely, duplication of Ube3a  results in poor social interaction, behavioral 
inflexibility, and anxiety (Smith et al. 2011).  Taken together, these data suggest that 
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there is a critical homeostatic level of Ube3a expression that must be maintained for 
normal neuronal function. 
In the present study, we evaluate changes in Ube3a expression in response to 
neuronal depolarization in vitro and neuronal activity in vivo. We present evidence that 
control of Ube3a expression is critical for activity-dependent kinase activation. These 
results better define the role of Ube3a in normal synaptic function in the CNS, expand 
our knowledge about the paternal Ube3a protein expression, and examine 
consequences of Ube3a absence in the context of neuronal activity. 
 
2.3. Materials and Methods 
2.3.1 Animals and reagents:  Animals: All animals utilized in the experiments were 
handled in accordance with protocols approved by the Institutional Animal Care and Use 
Committee of the University of South Florida. To generate paternally imprinted Ube3a-
YFP, C57 females were bred to Ube3a-YFP males. Maternal Ube3a-YFP mutants were 
obtained by the opposite crosses. 3-3.5 months old pUbe3a-YFP males and females 
were used in fear conditioning experiments to establish Ube3a expressional profiles. 
129SV/C57 hybrid Ube3a m+/p- and wild type littermates 2-4 months old were used to 
assess p-ERK activation. Antibodies: E6-AP (Bethyl lab); actin, ERK1/2, p-ERK1/2, 
MEK1/2, p-MEK1/2, Histone H3, HSP90 (Cell signaling); NeuN (Millipore), ApoER2 
(Abcam). Chemicals: KCl (Sigma, P9549, 50 mM).  
2.3.2 Fear conditioning and tissue collection. Paternal Ube3a-YFP mice were handled 5 
min/day for 5 days in the room where fear conditioning training took place. On the day of 
experiment, each animal was placed in a sound attenuation chamber (SAC) for 4.5 min: 
after 3 minutes of habituation 3 0.5 mA shocks with 30 sec intervals were applied to a 
floor grid.  Mice were euthanized with isoflourine at 5 min, 15 min, 1 hr, 3 hr, 6 hr 
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following conditioning (three animals per group, males and females). Mouse brains were 
removed and cortex and hippocampus were dissected in ice-cold PBS containing Halt 
protease and phosphatase inhibitors Cocktail (Thermo Scientific, 78440). Dissected 
tissue was frozen on dry ice and stored at -80º C until further processing. A control 
group of mice was subjected to fear conditioning training and was tested 24 hours later. 
Freezing behavior was recorded and scored by AnyMaze software. 
2.3.3 Western Blot (WB): Frozen tissue and primary neuronal cultures were 
homogenized by sonication in ice-cold RIPA buffer buffer (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 2 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% triton X100) 
containing Halt protease and phosphatase inhibitors cocktail. The lysates were clarified 
at 22,000 g for 30 min. The protein concentrations were determined using the BCA 
Protein Analysis Kit (Pierce, Rockford, IL). Samples were resolved by 10% TGX gels 
(Bio-Rad) and transferred to PVDF membrane.  Membranes were blocked with 5% milk 
in TBST (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween-20) for 1 hour and 
incubated with primary antibodies at 4ºC overnight. After 3 times 10 min washes with 
TBST , secondary antibodies were applied for 1 hr at room temperature. Blots were 
detected with film for chemiluminescence using Pierce ECL. Developed images were 
analyzed using ImageJ software. Statistical analysis (Student t-test, ANOVA) was 
performed using GraphPad Software. 
2.3.4 Subcellular fractionation. Mouse brains and murine mixed primary neuronal 
cultures were fractionated using the Subcellular Protein Fractionation Kit for Cultured 
Cells (Thermo scientific, 78840) according to manufacture manual. 
2.3.5 Primary neuronal culture: Mixed (cortical and hippocampal) cultures were used for 
western blot analysis and subcellular fractionation. Brains from E16-E18 wild type 129Sv 
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embryos were removed and dissected under microscope in ice-cold isotonic buffer (137 
mM NaCl, 5.4 mM KCl, 170 μM Na2HPO4, 148 μM K2HPO4, 5.5 mM glucose, 58.4 mM 
sucrose). Dissected tissue was pooled together in 15 mL tube and incubated with 1 mL 
0.25% trypsin for 5 minutes at 37ºC. Trypsin was removed and 5 mL dissociation media 
was added (DMEM, high glucose, 10% heat inactivate FBS, 1X antimycotic/antibacterial 
solution). Hippocampi were dissociated by slowly pipetting through glass pipettes. After 
brief centrifugation, dissociation media was replaced by neurobasal medium 
supplemented with 2% B27 and 0.5 mM glutamax. Cells were plated in 6 well 
(2,500,000/ well) plates coated with poly-l-lysine. Cultures were treated with 55 mM KCl 
on DIV 7-10. 
2.3.6 Non-fluorescent Immunohistochemistry. Mice were transcardially-perfused with 
saline solution (0.9% NaCl in water) followed by 4% PFA diluted in 0.1M PBS. Removed 
brains were dehydrated via sucrose gradient (10%, 20%, 30%) and sectioned on a 
cryostat at 30μm. Free-floating sections were blocked in 4% goat serum, 0.2% lysine in 
0.1 M PBS and incubated with Ube3a primary antibody overnight (1:1000). 
Secondary antibody  were added for 2 hours and the avidin-biotin-HRP complex was 
formed with VECTASTAIN® ABC kit (Vector labs). DAB was used to develop the stain. 
Sections were imaged with a Zeiss Mirax Scan 150 microscope. Identification of positive 
staining and percent area of positive stain was performed using Image Analysis software 
(created by Andrew Lesniak, Zeiss, www.nearcyte.org). 
2.3.7 Acute hippocampal slice preparation and treatment. 2 month old m-/p+ and m+/p+ 
littermates were sacrificed by decapitation, the brains were rapidly removed and briefly 
submerged in ice-cold cutting solution (110 mM sucrose, 60 mM NaCl, 3 mM KCl, 1.25 
mM NaH2PO4, 28 mM NaHCO3, 0.5 mM CaCl2, 5 mM Glucose, and 0.6 mM ascorbate) 
saturated with 95% O2 and 5% CO2. Hippocampal slices (400 μm) were cut on a 
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vibratome and allowed to equilibrate in artificial cerebrospinal fluid solution (125 
mM NaCl, 2.5 mM KCl, 1.24 mM NaH2PO4, 25 mM NaHCO3, 10 mM Glucose, 2 mM  
CaCl2, and 1 mM MgCl2) at 32ºC for  2 hours. Slices were treated with 55 mM KCl for 5 
and 30 minutes, snap frozen and stored at -80ºC for further processing. 
 
2.4 Results 
2.4.1 Ube3a expression changes in primary neurons immediately after neuronal 
depolarization. 
Maternal Ube3a protein is present in the neuronal nucleus, soma and dendrites, 
and is enriched in the postsynaptic compartment (Dindot et al. 2008; Gustin et al. 2010). 
Subcellular fractionation was used to isolate soluble and non-soluble nuclear, membrane 
and cytosolic compartments (Figure 2.1). To verify the specificity of the Ube3a antibody, 
hippocampi from Ube3a deficient mice (Ube3a m-/p-) and littermate controls were 
fractionated. The antibody shows specificity to Ube3a (approximately 110 kDa) with a 
complete absence of reactivity in Ube3a m-/p- mice. We observed a single unidentified 
protein band of a slightly higher molecular weight detected in the nuclear and chromatin-
bound fractions. We confirmed quality of fractions by detection of HSP90, ApoER2, 
NeuN and histone H3 to the cytosolic, membrane, nuclear and chromatin-associated 
fractions, respectively (Figure 2.1). Consistent with previous reports (Gustin et al. 2010), 
we find that Ube3a is enriched in the cytosol with lower detection in the nucleus and 
membrane compartments.  
Next, we determined if synaptic depolarization could modulate Ube3a protein 
expression in neuronal culture.  Mixed primary cultures (DIV 8-10) prepared from E17-18 
wild type brains were depolarized with 55 mM of KCl for 5 and 30 minutes. Western blot 
analysis revealed that Ube3a expression following KCl treatment is significantly 
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increased in the nucleus and cytosol as early as 5 minutes (nuclear soluble 201 ± 
21.42%,*p<0.05; cytosol 153.5 ± 16.59%, *p<0.05) and remained elevated up to 30 
minutes (nucleus 182.4 ± 34.78%, *p<0.05; cytosol 167.3 ± 17.51%, **p<0.01) (Figure 
2.2 A-D). Ube3a was slightly down-regulated in the membrane fraction at 30 min; 
however, the decrease failed to reach statistical significance. These data demonstrate 
that KCl induced depolarization affects Ube3a protein levels resulting in increased 
Ube3a expression in the cytosol and the nucleus.  
2.4.2 Consequences of Ube3a absence on depolarization-induced kinase activation. 
The wide variety and severity of AS symptoms suggests that the loss of Ube3a 
causes a global disruption of synaptic function. This is supported in the AS mouse model 
with identified synaptic disruption in the visual cortex, cerebellum and hippocampus 
(Jiang et al. 1998; Heck et al. 2008; Yashiro et al. 2009). A multitude of Ca2+- 
dependent signal transduction pathways are stimulated by synaptic depolarization. 
Previously, basal levels of several kinases important for LTP induction and maintenance 
in the hippocampus of AS mice were examined in the attempt to identify direct or indirect 
targets of Ube3a ubiquitination. In this study, we sought to revisit the p44/p42 
extracellular signal-regulated kinase (ERK1/2) and evaluate its response to neuronal 
depolarization in wild type (Ube3a m+/p+) and Ube3a-deficient mice (Ube3a m-/p+). The 
necessity of ERK p44/p42 (ERK1/2) is well established for synaptic plasticity and 
memory formation (English and Sweatt 1997; Atkins et al. 1998; Thomas and Huganir 
2004).  
Acute hippocampal slices from Ube3a m-/p+ mice and wild type littermates were 
treated with 55mM KCl for 5 or 30 minutes. Following Western blotting, the levels of total 
and phosphorylated ERK1/2 (p-ERK, Thr202/Tyr204) and mitogen-activated kinase 
kinase 1/2 (MEK1/2, p-MEK (Ser217/221)) were analyzed. Under basal conditions, 
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Ube3a m+/p+ and Ube3a m-/p+ groups (n=6-7 slices, 3 animals per genotype) had 
similar levels of total ERK1/2 and p-ERK (Figure 2.3 A, B). ERK1/2 activation was 
determined by same blot p-ERK to total ERK ratio and standardized to non-treated 
controls within genotype. All treated groups show elevated p-ERK after depolarization; 
however, p-ERK levels in Ube3a m-/p+ slices (p-ERK1: 311 ± 20.83 %; p-ERK2: 207 ± 
16.98%; **p<0.01, two-way ANOVA) failed to reach wild type levels (p-ERK1: 477.2 ± 
57.65; p-ERK2: 354 ± 80%) at 5 minutes post depolarization (Figure 2.3 C and D). 
Interestingly, levels were elevated from basal levels in both groups 30 minutes post 
depolarization, but were not significantly different (n=6 per genotype). Basal expression, 
phosphorylation and activation of MEK was not affected by the absence of Ube3a 
(Figure 2.3 E and F). These data suggest that after neuronal depolarization only the 
immediate activation of ERK is impaired. 
2.4.3 Spatial and temporal properties of Ube3a expression following fear conditioning 
training. 
Next, we wanted to determine if similarities in the observed changes exist for 
Ube3a and ERK1/2 in vivo. Recent reports suggest a dynamic regulation of Ube3a and a 
close integration of this regulation with synaptic plasticity in wild type mouse brain (Greer 
et al. 2010). The Ube3a allele is believed to show biallelic expression in all cell types, 
with the exception of neurons. However, maternal deletion shows a near 100% absence 
of Ube3a detection in the CNS (Figure 2.4 A-C). Increased Western blot exposure 
reveals Ube3a protein that cannot be detected in the Ube3a m-/p- mouse brain (Figure 
3). This observation raises the question of whether dynamic regulation of the paternal 
allele is occurring, albeit at a reduced expression, or if the detection of protein is from  
non-neuronal sources. Therefore, we sought to determine if both maternal and paternal 
copies respond to neuronal activation. The heterozygous Ube3a-Yellow Fluorescent 
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Protein (Ube3a-YFP) fusion protein reporter mouse allows the ability to distinguish 
paternal from maternal protein expression by increasing the molecular weight of a single 
allele with the addition of the YFP. Figure 2.5 C shows that paternal Ube3a-YFP is 
resolved higher than maternal due to the presence of the 20 kD YFP tag. Using this 
strategy, we next sought to determine if Ube3a protein changes could be detected with 
in vivo synaptic activity following fear conditioned associative memory formation. Fear 
conditioning (FC) was performed using a three foot-shock paradigm. To verify that this 
training paradigm leads to robust memory formation, a separate group of paternal 
Ube3a-YFP mice is shown to have a significant increase in freezing behavior compared 
to a no shock, context only group (Figure 2.5 D). Western blot analysis of the whole 
hippocampus and cortex collected at 5min, 15 min, 1hr, 3 hr and 6 hr intervals post 
training revealed significant changes in maternal Ube3a expression in the hippocampus 
(149.6 ± 14.68 %; *p<0.05)  and  cortex (378.4 ± 78.15 %; ***p<0.001) at 6 hr after FC 
when compared to control group (Figure 2.6 4 A-D). Remarkably, paternal Ube3a was 
significantly elevated only in hippocampus (1hr: 185.6 ± 15.82 %; 3 hr: 196 ± 14.05 %; 6 
hr: 210 ± 19.65 %; **p<0.01) of pUbe3a-YFP mice starting at the 1 hour time point; 
however, no similar response was observed in cortical samples (Figure 2.6 A-D). To 
evaluate if exposure to the context could result in altered Ube3a expression, a group of 
naïve  mice (handled only) was examined and showed  no difference  (data not shown). 
To determine if paternal Ube3a-YFP is affected by the inclusion of YFP, maternal 
Ube3a-YFP animals were generated and Ube3a-YFP was compared to naïve Ube3a. 
We found reduced maternal (86.6 ± 3.38 %; *p<0.05) or paternal Ube3a (56 ± 13.56 %; 
**p<0.01) expression of the Ube3a-YFP fusion protein compared to naïve wild type 
protein (Figure 2.5 A and B). 
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 Taken together our results suggest that both maternal and paternal alleles are 
activated by synaptic activity. It appears that paternal Ube3a expression has a specific 
temporal expression profile that is similar to the maternal activation in hippocampus, but 
not in cortex. Paternal Ube3a comprises about 3-5% of total Ube3a in neurons; thus, the 
amount of paternal protein increase is negligible. Nevertheless, it is critical to consider 
and further characterize the paternal Ube3a allele, especially given the growing interest 
in gene-based therapy approaches.  
2.4.4 Activity-dependent p-ERK disregulation in Ube3a deficient mouse model. 
 Reduced ERK activation in response to neuronal stimulation may contribute to 
the cognitive disruption present in Ube3a maternal deficient mice and human AS. 
Numerous studies report that reduction in ERK activity disrupts associative fear 
conditioned memory formation (Blum et al. 1999; Selcher et al. 2003). Next we 
determined if hippocampal-dependent associative learning in adult Ube3a m-/p+ showed 
reduced p-ERK activation in area CA1 following a 3 foot shock FC paradigm. This 
experimental approach has previously shown increased ERK activation in area CA1 of 
the hippocampus (Chwang et al. 2006). We subjected both Ube3a m+/p+ (n=5 control, 
n=6 experimental) and Ube3a m-/p+ (n=5 for control, n=4 experimental) 3-4 month old 
mice to FC and measured pERK levels in CA1 60 minutes after to FC training. No 
significant change in total ERK1/2 or p-ERK1/2 was observed at baseline (Figure 2.7 B). 
Significant differences in p-ERK activation became apparent when the samples were 
compared at 60 minutes post training. Consistent with published data (Chwang et al. 
2006) area CA1 of Ube3a m+/p+ hippocampi showed a significant increase in p-ERK2 
levels (143.4 ± 14.19 % of Ube3a m+/p+, *p<0.05) compared to control group. By 
comparison, p-ERK2 activation was blunted in Ube3a m-/p+ animals (82.10 ± 4.6 % of 
Ube3a m-/p+ controls).  
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(Figure 2.7 C). Analysis of CA3 and DG areas didn‘t reveal changes in total or p-ERK in 
either wild type or in transgenic littermates (Figure 2.8 A-D). 
 
2.5 Discussion 
A preponderance of imprinted genes is associated with placental regulation and 
represents a genetically unique method of regulating protein expression. However, 
maternal Ube3a levels can undergo further regulation beyond paternal allele silencing. 
For example, Ube3a is a target of itself, suggesting a negative feedback for regulating 
protein level. This form of biochemical regulation may be in response to the recent 
discovery of altered neuronal Ube3a expression following glutamatergic activation and 
neuronal depolarization. A wide variety of activators including N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and brain-
derived neurotrophic factor (BDNF) can initiate an increase of Ube3a mRNA within 5 
hours in primary cultures (Greer et al. 2010). In light of direct and indirect alterations of 
Arc and CaMKII, both major players in synaptic plasticity, changes in Ube3a expression 
suggests a role in synaptic function that supersedes the traditional roles of an E3 
ubiquitin ligase.  We sought to determine if Ube3a is altered in response to neuronal 
depolarization and in vivo learning and memory. Furthermore, we wanted to investigate 
if other signaling proteins modulated by calcium influx were likewise altered during 
synaptic activity in the Angelman syndrome mouse model. 
While we did not specifically delineate isoform expression, we find increased total 
Ube3a in response to KCl treatment at 5 and 30 minutes post application in both 
cytosolic and nuclear fractions isolated form primary neurons suggesting that this is not 
an isoform-dependent phenomenon. Although ubiquitously-expressed, Ube3a localizes 
to the nucleus where it serves as a transcriptional co-activator and plays a role in the 
chromosome segregation (Nawaz et al. 1999; Singhmar and Kumar 2011). Nuclear 
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association is also expected due to other Ube3a targets including p53, p27 or HHR23A 
(Jiang et al. 1998; Kumar et al. 1999; Mishra and Jana 2008; Mishra et al. 2009). 
However, the potential role for up-regulation of nuclear associated Ube3a is yet to be 
determined.  Greer and colleagues (2010) reported that Ube3a mRNA is up-regulated in 
mouse hippocampus 1 hour following novel environment exploration task. In our study 
we utilize the 3 foot shock fear conditioning paradigm to examine spatial and temporal 
Ube3a changes in the paternal Ube3a-YFP reporter mouse brain. This particular model 
allows quantification of both maternal and paternal proteins due to the differential 
molecular weight of the paternal-derived Ube3a-YFP protein. Our results demonstrate 
an increase in both maternal and paternal Ube3a expression starting at 1 hour post 
training in hippocampus, while only maternal Ube3a expression is increased in the 
cortex. The spatial differences in expression profiles may reflect the behavioral 
paradigm, as fear conditioning is a hippocampal-dependent behavioral task requiring 
extensive coordination of hippocampal pyramidal cell activity. Alternatively, the cortex 
may represent a brain region where the imprinting center at 15q11 is much more tightly 
regulated and the silencing mechanism is more stringent or insensitive to fear 
conditioning. However, it is intriguing to find that neuronal activity might be sufficient to 
overcome epigenetic silencing and allow, albeit modest, production of the paternal 
Ube3a protein.  
Identifying activity dependent regulation of Ube3a protein raises the possibility 
that Ube3a is involved in activities other than housekeeping protein degradation. It 
stands to reason that Ube3a may be involved in modulating pathways that are involved 
in synaptic plasticity, and this may explain why our earlier work investigating kinase 
alterations in the Ube3a maternal deficient mouse only revealed an alteration in alpha-
CaMKII phosphorylation (Weeber, 2003). Those previous experiments were performed 
during basal conditions. The use of KCl-induced neuronal depolarization should 
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effectively activate multiple signaling pathways leading to ERK activation. Interestingly, 
we demonstrate reduced phosphorylation of ERK in response to KCl depolarization in 
the Ube3a m-/p+ mouse, suggesting that Ube3a is involved in a signaling cascade that 
targets ERK phosphorylation. Curiously, we did not find a concurrent difference in either 
total MEK or phospho-MEK levels, the kinase responsible for phosphorylation and 
activation of ERK. This result may reflect a direct or indirect action of Ube3a on MEK‘s 
ability to phosphorylate ERK or an Ube3a-dependent regulation of phosphatases. The 
exact mechanism for this difference in ERK activation is currently under investigation.   
There has been extensive investigation into the regulation of ERK in mice 
performing various behavioral tasks. Depending on the learning paradigm, the p-ERK 
levels are shown to increase as early as 1 minute post training and stay elevated for up 
to 9 hrs (Blum et al. 1999; Chwang et al. 2006; Trifilieff et al. 2006; Trifilieff et al. 2007).  
Both memory formation and hippocampal synaptic plasticity are sensitive to inhibition of 
ERK activation and reduced p-ERK levels correlate nicely with deficits in memory 
retention (Blum et al. 1999; Selcher et al. 1999). Our finding that p-ERK levels are 
reduced following contextual fear conditioning in Ube3a m-/p+ mice provides an 
additional rationale to explain the well-established associative learning deficit exhibited 
by these mice (Jiang, 1998 ; van Woerden, 2007 ;Huang, 2013).  
In conclusion, the present study suggests that Ube3a protein levels can change 
significantly in response to neuronal depolarization, and importantly, during the 
processes of associative learning and memory. Increased levels in both maternal and 
paternal Ube3a are intriguing and raise important questions about regulatory 
mechanisms of both maternal and paternal alleles. Furthermore, subtle changes in the 
paternal Ube3a allele, its distribution, isoform production and function should be 
addressed before considering it as a potential therapeutic target. 
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Figure 2.1. Subcellular fractionation of a mouse brain. Subcellular fractionation 
technique was used to isolate cellular fractions with minimal cross-contamination. CEB-
cytosolic, MEB–membrane, NEB–nuclear soluble, CRB–chromatin-bound. 
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Figure 2.2. Ube3a expression changes in cytosol and nucleus following 55mM 
KCl application. A and B. Representative western blot of Ube3a total protein increase 
in cytosolic and nuclear fractions at 5 min (A) and 30 min (B) following 55mM KCl 
stimulation in primary neuronal cultures (DIV 8-10). Ube3a is shown in 2 exposures 
(low–upper panel, high–lower panel). NT- non-treated control.  C-D. Quantification of 
western blot analysis (n=5, treatments standardized to NT group, one way ANOVA, 
post hoc Tukey‘s test, *p<0.05, **p<0.01). 
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Figure 2.3.  Reduced KCl depolarization-dependent p-ERK phosphorylation in 
acute hippocampal slices of Ube3a m-/p+ mice. A. Representative immunoblot. B 
and E. Levels of total ERK and total MEK1/2 are unchanged in m-/p+ mice. C and D. 
Quantitative Western blot analysis shows significantly decreased levels in pERK1/2 
activation in hippocampal slices of Ube3a m-/p+ mice at 5 minutes but not 30 minutes 
after 55mM KCl application (n=5, treatments standardized to NT group within 
genotype, two-way ANOVA, post hoc Tukey‘s test, *p<0.05, **p<0.01). F. KCl induced 
phosphorylation of MEK1/2 is normal in both genotypes 
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actin
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Figure 2.4. Ube3a expression in Ube3a m+/p+, Ube3a m-/p+ and Ube3a m-/p- mouse 
brains. A. Paternal Ube3a is expressed at low levels throughout in the Ube3a m-/p+ 
mouse brain. HIP-hippocampus, PFC-prefrontal cortex, COR–cortex, STR–striatum, 
CER–cerebellum. Immunostaining (B) and subsequent analysis (C) of coronal sections of 
mouse brain demonstrated nearly absence of paternal Ube3a expression in Ube3a m-/p+ 
mice (n=3) and no Ube3a expression in Ube3a m-/p- (n=2) compared to wild type controls 
(n=3) (one-way ANOVA, post hoc Tukey‘s test, *p<0.05). 
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Figure 2.5. Ube3a expression in Ube3a-YFP reporter mice. C. YFP-tagged Ube3a 
has higher molecular weight then wild type Ube3a. Depending on the paternal 
transmission, animals can carry an imprinted paternal Ube3a-YFP gene and wild type 
maternal gene (pUbe3a-YFP) or imprinted paternal wild type Ube3a and maternal 
Ube3a-YFP (mUbe3a-YFP). Addition of YFP affects basal expression of Ube3a. 
Expression of mUbe3a-YFP and pUbe3a proteins are significantly reduced compared 
to wild type mUbe3a (A) and pUbe3a (B) respectively (mUbe3a-YFP, n=6; pUbe3a-
YFP, n=4); Student‘s t-test, *p<0.05, **p<0.01). D. pUbe3aYFP animals that received 3 
shocks freeze significantly more than littermate pUbe3aYFP controls 24 hrs later. (n=5 
per group; Student t-test, df=8, ***p<0.001). 
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Figure 2.6. Changes in maternal and paternal Ube3a expression following 
contextual fear conditioning. Paternal Ube3a-YFP mice received 3 shocks. mUbe3a 
expression is elevated starting at 1hour and significantly increased in the hippocampus 
(C) and cortex (D) of pUbe3a-YFP animals at 6 hr. pUbe3a-YFP is only increased in 
hippocampus. All the time points are normalized and compared to ―context only‖ control 
group (ctr). (n=3 per group; one-way ANOVA; Tukey‘s post hoc test; *p<0.05, **p<0.01, 
***p<0.001). 
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Figure 2.7. Disregulation of p-ERK activation in Ube3a m-/p+ mouse brain 
following fear conditioning.  A and C.  Ube3a m-/p+ and their littermate controls 
were subjected to a 3 shocks conditioning paradigm. ERK1/2 phosphorylation was 
determined by densitometry. p-ERK2 expression was significantly increased in wild 
type CA1 hippocampal region (n = 4-5 per group; one-way ANOVA; Tukey‘s post hoc 
test; *p<0.05, **p<0.01). Fear conditioning failed to induce the same changes in 
Ube3a m-/p+ mice. B and D. There was no change in p-ERK1/2 or total ERK1/2 
expression between Ube3a deficient and littermate control groups.   
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Figure 2.8. No abnormal ERK 2 phosphorylation was found in dentate gyrus and 
CA3 areas of Ube3a m-/p+ mouse brain following fear conditioning.  A and B. 
There was no change in basal p-ERK 2 expression in dentate gyrus (DG) or CA3 area 
(CA3) between Ube3a deficient and littermate control groups. C and D. Fear 
conditioning didn‘t induce any changes in DG and CA3 of neither Ube3a m-/p+ nor 
Ube3a m+/p+ animals (n = 4-5 per group).  
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CHAPTER 3: MOLECULAR MECHANISMS UNDERLYING THE HIPPOCAMPAL 
 
LTD IMPAIRMENT IN THE ANGELMAN SYNDROME MOUSE MODEL 
 
3.1 Abstract 
Long-term potentiation (LTP) and long-term depression (LTD) are the forms of 
experience-driven synaptic plasticity that coexists in the brain. Protein degradation is 
highly involved in both of these processes; thus, any alteration to the ubiquitin 
proteasome pathways may lead to abnormal neuronal transmission. For example, 
genetic deficits in UBE3A, E3-ligase that targets specific substrates for degradation 
results in Angelman Syndrome (AS). Ube3a-deficient mice show an impaired 
hippocampal LTP that corresponds to poor performance in hippocampal-dependent 
behavioral tasks such as contextual fear conditioning and the hidden platform water 
maze. Unfortunately, as much effort has been directed towards elucidating molecular 
mechanisms underlying LTP defects, LTD has received little attention. In the present 
study we have investigated the role of Ube3a in both hippocampal NMDAR-dependent 
and NMDAR-independent LTD. We found that the magnitude of synaptic depression 
was reduced in response to NMDAR and mGluR1/5 stimulations in AS mice. 
Additionally, we examined mGluR1/5 signal transduction cascade to determine if any 
changes in major pathway elements could explain the observed phenotype. No 
alteration in mGluR1/5-induced kinase activation was detected; however, an abnormal 
GluR2 distribution was observed. Our results suggest that Ube3a may play a greater 
part in overall synaptic plasticity as it contributes not only to hippocampal LTP but also to 
LTD expression.  
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3.2 Introduction 
 Angelman syndrome (AS) is a rare childhood disorder with no preference to race, 
ethnicity or gender. From an early age AS manifests as a delay of the major motor and 
cognitive milestones, seizures, a complete absence of speech, excessive smiling and 
laughter (Clayton-Smith and Laan 2003; Williams et al. 2006). AS is associated with the 
UBE3A allele located on the imprinted region of 15q11-13 human chromosome (Kishino 
et al. 1997; Matsuura et al. 1997). Maternal gene disruption through deletion, mutation, 
unipaternal disomy or methylation defects results in nearly all cases of the disorder 
(Lossie et al. 2001; Dagli et al. 2011).  To date there are no accepted, specific treatment 
for AS beyond standard therapy for seizure control.  
The specific molecular role Ube3a may play in the process underlying the 
cognition disruption is under active investigation. The UBE3A gene encodes an E3-
ubiquitin ligase that targets specific proteins for degradation and shows neuron-specific 
paternal imprinting in humans and mice (Huibregtse et al. 1993; Scheffner et al. 1993; 
Jiang et al. 1998; Gustin et al. 2010; Daily et al. 2012). The accumulation of Ube3a 
substrates, produced by the Ube3a loss, is considered the main cause of the AS 
pathology (Mabb et al. 2011). Several transgenic mouse models are currently available 
to study Ube3a localization, function, and contribution in synaptic plasticity (Jiang et al. 
1998; Miura et al. 2002; Dindot et al. 2008; Jiang et al. 2010). Ube3a deficient animals 
nicely recapitulate some of the AS phenotype observed in humans. Beyond this, the 
murine model produced through a null mutation of the maternal Ube3a exhibits 
impairment in long-term potentiation (LTP) that may translate into poor performance in 
hippocampal-dependent behavioral tasks such as contextual fear conditioning and the 
hidden platform water maze (Jiang et al. 1998). Interestingly, the synaptic plasticity and 
learning and memory defects can be reversed by genetic or protein replacement 
manipulations (van Woerden et al. 2007; Daily et al. 2011; Kaphzan et al. 2013). 
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 The majority of literature examining synaptic function in the AS mouse model 
has focused on the mechanisms responsible for the LTP deficit. Several hypotheses 
have been proposed to address the decrease in excitatory synaptic transmission and 
behavioral phenotype. Specifically, an aberrant CaMKII phosphorylation and reduced 
activity-dependent ERK activation (Chapter 1) together with the altered phosphatase 
activity have been suggested as potential mechanisms responsible for cognitive 
disruption (Weeber et al. 2003). Additionally, accumulation of Ube3a substrates and 
increased expression of a few proteins such as Arc and α1 subunit of Na/K ATPase 
have been shown to contribute to the neuronal dysfunction (Greer et al. 2010; Kaphzan 
et al. 2011; Kaphzan et al. 2013). While LTP is the most studied in vitro model of 
learning and memory, it is not the only form of experience –driven synaptic plasticity that 
exists in the brain (Malenka and Bear 2004). Long-term depression (LTD) represents a 
different kind of long-term plasticity that elicits a variety of long-lasting changes through 
the modification of synapses, promoting a long-lasting decrease in the strength and the 
efficacy of the synaptic transmission. Electrophysiological data collected from the 
maternal Ube3a-deficient animals demonstrate a necessity of Ube3a for excitatory 
neuronal transmission; however, sparse evidence exists to assess the role of Ube3a in 
LTD. A single study by Yashimo et al. reports that the absence of Ube3a leads to 
biodirectional impairment in both LTP and LTD in the mouse visual cortex (Yashiro et al. 
2009).  The authors suggest that the deficit in the plasticity might be explained by an 
increase of LTD induction threshold or possibly of an abnormal neurotransmitter release 
caused by abnormal spine number. However, these possibilities are yet to be tested.  
In present study, we focused on elucidating the role of Ube3a in hippocampal 
LTD expression. We examined mGluR1/5 signal transduction cascade and AMPAR 
expression to determine the molecular mechanisms underlying LTD deficits in Ube3a 
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deficient mice. Our results suggest that altered synaptic depression may add to the 
overall cognitive phenotype observed in AS mouse model. 
 
3.3 Material and Methods 
3.3.1 Animals: Animals utilized in the experiments were handled in accordance with 
protocols approved by the Institutional Animal Care and Use Committee of the University 
of South Florida. 129-Ube3a deficient mice were grouped and housed in a standard 12 
hour light/dark cycle and fed mouse chow ad libitum. 
3.3.2 Electrophysiology: 21-30 day old 129SVE Ube3a deficient (Ube3a m-/p+) and wild 
type littermates (Ube3a m+/p+) were used to assess NMDAR – dependent (NMDAR-
LTD) and NMDAR – independent LTD (mGluR-LTD). 6-8 week old animals were used to 
investigate DHPG – induced LTD. Ube3a m-/p+ and Ube3a m+/p+ littermates (both 
genders) were sacrificed by decapitation, the brains were rapidly removed and briefly 
submerged in ice-cold cutting solution (110 mM sucrose, 60 mM NaCl, 3 mM KCl, 1.25 
mM NaH2PO4, 28 mM NaHCO3, 0.5 mM CaCl2, 5 mM Glucose, and 0.6 mM ascorbate) 
saturated with 95% O2 / 5% CO2. Hippocampal slices (400 μm) were cut on a vibratome 
and allowed to equilibrate in artificial cerebrospinal fluid solution (ACSF) (124 mM NaCl, 
5 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM Glucose, 2 mM CaCl2, and 1 
mM MgCl2) at 30ºC for at least 2 hours prior to recording. The recording chamber was 
maintained at 30º with ACSF flow rate at 1mL/min. Field excitatory postsynaptic 
potentials (fEPSPs) were elicited via stimulation of Schaffer collaterals in the CA3 
hippocampal area and recorded from stratum radiatum of CA1 via glass micropipettes 
pulled to an approximate tip diameter of 1 μm (1–4 MΩ) and loaded with ACSF. The 
delivery of stimulation was controlled by pClamp 9.0 software (Axon Instruments, Forster 
City, California, USA), a Digidata 1322A interface (Axon Instruments), and stimulus 
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isolator (model 2200, A-M Systems, Sequim, Washington, USA). All signals were 
amplified using a differential amplifier (model 1800, A-M Systems), filtered at 1 kHz and 
digitized at 10 kHz. Stimulus intensity was set to 50%-60% of the maximum fEPSP 
response as determined from the input-output curve. The baseline responses were 
collected every 30 seconds for 20 min.  Input-output relationships were determined by 
stimulating slices from 1-15 mV at 0.5 mV increments. Short-term plasticity was 
measured via paired-pulse facilitation which was induced by stimulating slices sequential 
pulses spaced at 20 ms intervals from 20-300 ms. NMDAR-LTD was induced by a PP-
LFS (paired-pulse low frequency stimulation) consisting of 900 pairs of stimuli (50-msec 
interstimulus interval) delivered at 1Hz. mGlur-LTD was induced by the same PP-LFS 
but in the presence of 50 µM D-AP5 (Tocris, 0805). DHPG-induced LTD was elicited by 
a brief application of freshly made 100 µM (S)-3,5-DHPG (Tocris, 0805) diluted in room 
temperature ACSF. For analysis, baseline slope was calculated from the mean slope 
values recorded for 20 minutes before the PP-LFS or DHPG treatment. LTD values were 
expressed as percentage of the fEPSPs standardized to baseline recordings. Statistical 
analysis was performed for the last 30 minutes of recording following NMDAR-LTD and 
DHPG-induced LTD, and 10-40 min post stimulation time interval for mGlur-LTD. 
3.3.3 Acute slice preparation and drug treatment: 350 µm brain slices were prepared as 
described above. After recovery at 30C for 2.5 hours slices, were treated with freshly 
made 100 µM (S)-3,5-DHPG for 5 minutes. CA1 area was dissected under the 
microscope at room temperature ACSF and flash frozen for further processing. 
3.3.4 Western Blot: Frozen tissue was homogenized by sonication (3 pulses) in ice-cold 
RIPA buffer (Thermo Scientific Pierce, # 89900) supplemented with 1X Halt protease 
and phosphatase inhibitors cocktails (Thermo Scientific Pierce, # 78440). The lysates 
were incubated on ice for 15 min and were clarified at 14,000 g for 15 min. The protein 
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concentrations were determined using the BCA Protein Analysis Kit (Thermo Scientific 
Pierce, 23227). Samples were resolved on 10% TGX gels (Bio-Rad) and transferred to 
PVDF membrane.  Membranes were blocked with 5% milk in TBST (50 mM Tris-HCl, pH 
7.5, 150 mM NaCl, and 0.1% Tween-20) for 1 hour and incubated with primary 
antibodies at 4ºC overnight or 1 hr at room temperature. After 3 10 minutes washes with 
TBST, secondary antibodies (Southern Biotech, 1:2000) were applied for 1 hour at room 
temperature. Immunoreactivity was detected using Pierce ECL. Developed images were 
analyzed by NIH ImageJ software. Statistical analysis (Student t-test, ANOVA) was 
performed using GraphPad Software. Antibodies: E6-AP (Bethyl Biolabs; 1:2000), Arc (a 
kind gift from Dr. Paul Worley; 1:200), β-actin (1:2000), p-ERK 1/2 (1:4000), ERK 1/2 
(1:10000), p-mTor (1:2000), mTor (1:3000), p-p38 MAP (1:1000), p38 MAP (1:1000) 
(Cell signaling). 
3.3.5 Surface protein labeling: 350 µm brain slices were prepared as described above. 
Slices were left at 30ºC to recover for 2 hours before surface biotinylation. EZ-Link Sulfo-
NHS-LC-Biotin (Thermo Scientific Pierce, # 21335) was equilibrated to room 
temperature and resuspended in cold ACSF at 1mg/mL. Slices were transfered to 1 mL 
of the ice-cold ACSF-biotin solution and were incubated for 45 minutes at 4ºC while  
slightly shaking. Tissue was  washed once  with ice-cold ACSF,  once with 25mM Tris 
(pH 8.1) to quench biotin, followed by 2 washed with ice cold 0.1M PBS (phosphate 
buffer saline, pH 7.4). Slices were lysed with 70 µL of cold RIPA buffer (1X alt protease 
and phosphatase inhibitors). Protein concentrations were determined with the BCA 
Protein Analysis Kit and samples were adjusted to 1 mg/ml.  40 µg of protein was added 
to 40 µL of NeutrAvidin Agarose beads (Thermo Scientific Piece, 29200) pre-washed 2 
times with room temperature PBS, 1 time with RIPA buffer and incubated at 4ºC 
overnight. Proteins were eluted with 35 µL of 2 X Lamelli buffer (Bio-Rad) at 95ºC for 10 
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minutes. 4 µg of lysates and eluted samples were resolved on 4-15% TGX gels (Bio-
Rad). The ratio of surface expression to total expression was used to determine surface 
levels of GluR1, GluR2. Antibody: GluR1, GluR2, mGlur1/5 (1:1000, Neuromab), NR2B 
(1:2000; Millipore), β-actin (1:3000, Cell Signaling ), E6-AP (Bethyl Biolabs; 1:2000). 
3.3.6 Hippocampal primary culture: Hippocampi from E16-E18 129SV/C57 embryos 
were quickly dissected in ice-cold isotonic buffer (137 mM NaCl, 5.4 mM KCl, 170 μM 
Na2HPO4, 148 μM K2HPO4, 5.5 mM glucose, 58.4 mM sucrose, briefly oxygenated with 
95% O2 / 5% C02). Tissue was incubated with 0.25% trypsin for 5 min at 37ºC and 
neurons were dissociated by titration. After brief centrifugation at 1500 rpm, cells were 
resuspended in 2 ml of fresh Neurobasal media and plated on 13 mm poly-D-lysine and 
laminin (Roche Applied Science, # 11243217001)  pre-treated glass coverslips at 35,000 
cells per well in 24 well plates. Cultures (DIV15-19) were stained for GluR1 and GluR2 to 
determine basal levels of receptors internalization and activity-dependent endocytosis.  
3.3.7 Immunocytochemistry: Internalized GluR1 and GluR2 staining. Low density 
primary hippocampal cultures were labeled live with N-terminus antibodies against 
GluR1 (Millipore, PC246; 1:15) and GluR2 (Millipore, MAB937; 1:75) for 20 min at 37ºC. 
Cultures were rinsed with cold 100 mM PBS (pH 7.4) and exposed to 0.5 M NaCl/0.2 
acetic acid (pH 3.5) for 4 min on ice to remove antibody bound to surface receptors. 
Coverslips were washed with PBS and fixed with 4% PFA /4% sucrose for 15 min. Cells 
were permeabilized with 0.1% Triton-X for 10 min and non-specific binding was blocked 
with 10% goat serum, 0.1% BSA, 0.1% Triton-X for 1 hr. Internalized GluR1 and GluR2 
were visualized with Alexa 488 or Alexa 546 secondary antibody (Invitrogen, 1:750). 
Surface GluR1 and GluR2 staining. Neurons were labeled as described above. Media 
containing antibody was removed and replaced with condition media containing 100 µM 
DHPG or water. After 5 min incubation with the drug, media was exchanged and cells 
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were allowed to incubate at 37ºC to promote AMPAR endocytosis. After 15 min, cultures 
were fixed with 4% PFA /4% sucrose, blocked with 10% goat serum, 0.1% BSA, for 1 hr 
and  visualized with Alexa 488 or Alexa 546 secondary antibody (Invitrogen, 1:250). 
Coverslips were imaged using the Olympus FV10i confocal microscope, 60X objective 
(z-stack). For comparison between genotypes or drug treatment, images were taken with 
the same exposure settings. Immunofluorescence of 3 dendrites per neuron was 
analyzed.  Images were thresholded, and pixel intensity of ROI was measured by NIH 
ImageJ software.  
3.3.8 .Statistical analysis: All data is shown as the mean ± S.E.M. Student‘s t-test and 
ANOVA (Tukey‘s post hoc test) were applied as appropriate. Statistical significance was 
determined when p < 0.05. 
 
3.4 Results 
3.4.1 Long-term depression is impaired in Ube3a m-/p+ mouse model 
It has been widely accepted that the loss of Ube3a expression manifests in long-
term potentiation (LTP) impairments (Jiang et al. 1998; Weeber et al. 2003; Yashiro et 
al. 2009). Therefore, we sought to address if Ube3a also contributes to a different form 
of synaptic plasticity such as hippocampal LTD. Hippocampal slices from young Ube3a 
m-/p+ mice (n=5 animals) and their littermate controls (n=5 animals) were stimulated via 
Schaffer collaterals in the CA3 area and the field excitatory postsynaptic potentials 
(fEPSPs) were recorded extracellularly from stratum radiatum. To determine if Ube3a is 
required for NMDAR-dependent LTD (NMDAR-LTD). Paired-pulse low frequency 
stimulation (PP-LFS; 900 paired pulses (50 ms interstimuli intervals) 1Hz) was delivered 
to Ube3a m-/p+ (n=8 slices, 4 animals) and wild type (n=9 slices, 4 animals) 
hippocampal slices and the resulting fEPSP slopes were analyzed (Figure 3.1 A and B). 
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PP-LFS induced depression of the fEPSPs in both genotypes; however, the Ube3a m-
/p+ mice displayed a significantly reduced synaptic response during the last 30 min of 
recording (83.87 % ± 4.162 of the baseline; *p<0.0205) when compared to the Ube3a 
m+/p+ littermates (67 % ± 4.669 of the baseline).  
A great body of literature suggests that two forms of LTD, NMDAR-LTD and 
mGluR-LTD, co-exist in the CA1 area of the hippocampus (Oliet et al. 1997; Bolshakov 
et al. 2000). To differentiate between them, we initially applied the same PP-LFS 
protocol but in the presence of 50 µM D-AP5 to eliminate the NMDAR component. A 
significant decrease in fEPSP slope was observed in Ube3a m-/p+ slices (n=10 slices, 4 
animals; 94.75 % ± 3.859 of the baseline; *p<0.0405) when compared to the wild type 
controls (n=8 slices, 4 animals; 80.46 % ± 5.319 of the baseline) at the 10-40 min post 
stimulation interval (Figure 3.2 A and B).  mGlur-LTD could also be elicited by an acute 
application of the selective mGluR1/5 agonist dihydroxyphenylglycine (DHPG) (Huber et 
al. 2001). Thus, we decided to investigate the effect of DHPG on the fEPSP slope of the 
Ube3a m-/p+ mice. As expected, a brief application of 100 µM DHPG triggered a 
dramatic synaptic depression in both groups (Figure 3.2 C and D). Statistical analysis of 
the last 30 min revealed  that the magnitude of DHPG-induced LTD was significantly 
decreased in the Ube3a m-/p+ mice (n=12 slices, 5  animals; 77.12 % ± 7.499 of the 
baseline; *p<0.05) compared to the Ube3a m+/p+ littermates (n=13 slices, 5 animals; 
57.46 % ± 3.895 of the baseline). Taken together, these data suggest a more general 
function of Ube3a in long-term synaptic plasticity. 
3.4.2 ERK 1/2 and mTOR activation is not affected by the loss of Ube3a 
Our results indicate that Ube3a is crucial not only for LTP induction and 
maintenance but also acts as an essential component of LTD expression. Next, we 
decided to focus on the well-studied mGlur1/5 signal transduction cascade to determine 
61 
 
if there are any alternations in the constitutive kinase expression and activation that may 
contribute to the impaired mGluR-LTD found in Ube3a m-/p+ mice. Empirical evidence 
demonstrate that mGluR-LTD requires  de novo protein synthesis that heavily relies on 
the activation of mitogen-activated protein kinases (MAPKs), such as p44/p42 
extracellular signal-regulated kinase (ERK 1/2) and p38, and mammalian target of 
rapamycin kinase (mTOR) (Gallagher et al. 2004; Hou and Klann 2004; Huang et al. 
2004; Banko et al. 2006; Moult et al. 2008). These pathways are eventually connected to 
the translation of mRNAs (Huber et al. 2000; Waung and Huber 2009). Initially, we 
examined the basal levels of these kinases in the CA1 area of hippocampal slices 
obtained from 4-6 week old Ube3a m-/p+  (n=12 slices, 4 animals) and the wild type 
littermates (n=8 slices, 3 animals). Western blot analysis revealed no change in the 
expression of ERK 1/2, mTOR or p38. (Figure 3.3 A and C). Additionally, no difference in 
the phosphorylation state between the genotypes was observed (data not shown).  
To ascertain that the kinase activation is not affected by the Ube3a absence, we 
utilized the ability of DHPG to activate mGluRs and subsequently phosphorylate ERK 
1/2 at Thr202/Tyr204, mTOR at Ser2448 and p38 at Thr180/Tyr182 residues. The 
hippocampal slices were treated with 100 μM DHPG for 5 min and kinase activation was 
determined by the same blot phospho-kinase to total kinase ratio and standardized to 
non-treated controls within genotype. All treated groups show similar elevated levels of 
p-ERK (Ube3a m+/p+: 266 % ± 40.23; Ube3a m-/p+: 261 % ± 18.66 of NT controls; 
***p<0.001) and p-mTOR (Ube3a m+/p+: 138.6 % ± 12.4; Ube3a m-/p+: 164.6 % ±  
21.56 of NT controls, *p<0.05) followed by DHPG application. Interestingly, activation of 
p-p38 was not noted in any of the groups (Figure 3.3 B, D and E). 
Our findings suggest that the mGluR-ERK 1/2 and mGluR-mTOR signaling is not 
modulated by Ube3a. These data led us to believe that new protein synthesis is not 
62 
 
affected in Ube3a m-/p+ mouse model. However, additional experimentation is needed 
to solidify this assumption. 
3.4.3 Arc expression is elevated in Ube3a m-/p+ CA3 area 
Activation of mGluRs induces rapid local translation of several proteins that are 
necessary for LTD expression (Waung and Huber 2009). One such ―LTD protein‖ Arc, is 
shown  to be regulated by Ube3a (Greer et al. 2010). To understand the involvement of 
Arc in the mGluR-LTD deficit, we measured the total levels of this protein in the CA1 
areas of Ube3a m-/p+ mice. Consistent with previously published data we observed a 
significant increase in Arc expression (239 % ± 42.81 of Ube3a m+/p+ littermates, 
*p<0.05) (Figure 3.4 B). Evidence suggests that Arc is actively translated in the response 
to mGluR stimulation (Park et al. 2008; Waung et al. 2008); therefore, we determined 
whether the DHPG-induced Arc dynamic is preserved under Ube3a-deficient conditions. 
Surprisingly, we discovered a significant up-regulation after 5 min of 100 μM  DHPG 
application only in the Ube3a m-/p+ samples  (n=12 slices, 200.5 % ± 27.71, *p<0.005), 
but not in wild type littermate (n=8 slices, 147.4 % ± 44.73, p=0.35) (Figure 3 D and E).  
 
3.4.4 Alternations in AMPAR subunits in Ube3a m-/p+ mice 
 Overexpression of Arc has been linked to the loss of surface AMPAR subunits. 
As the dysregulation of GluR1 endocytosis has already been reported in the AS mouse  
model, we sought to focus on Glur2 expression. Additionally, apart from GluR1, GluR2 
subunits have been implicated in the mGluR-LTD (Zhou et al. 2011); therefore any 
alteration in its expression may explain a reduction in mGluR-LTD observed in Ube3a m-
/p+ mice. To explore the consequences of elevated Arc on the basal GluR 2 abundance, 
we utilized the receptor biotinylation technique. Results show the total expression of 
GluR2 subunit (73 % ± 6.7 of Ube3a m+/p+ littermates, **p<0.01) was decreased in 
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hippocampal lysate isolated from 4-6 weeks old Ube3a m-/p+ mice (n=7 slices, 3 
animals) when compared to Ube3a m+/p+ controls (7 slices, 3 animals).  No change was 
detected in NR2B (Figure 3.5 A and B).  The analysis of surface receptor expression 
was achieved by normalizing biotinylated fraction to the total proteins within the same 
sample. The quantification of surface proteins showed no change in NR2B and GluR1; 
however, GluR2 levels were greatly reduced in Ube3a m-/p+ samples (63.3 % ± 8.8 of 
Ube3a m+/p+ littermates, *p<0.05) 
 Based on our findings we sought to determine if a decrease surface receptors 
levels would translate into an increased internal GluR2. We then measured the 
abundance of internalized GluR2 (iGluR2) by immunocytochemistry. Live antibody 
labeling and acid-strip approach has been successfully used to determine internal 
AMPAR expression (Snyder et al. 2001). Using a similar method, we found that the 
dendritic iGluR2 was significantly up-regulated in mature Ube3a m-/p+ hippocampal 
cultures (n=15 cells; 115.4 ± 4.2, *p<0.05) compared to non-transgenic controls (n=15 
cells) (Figure 3.5 C). Finally, we hypothesized that the altered levels of AMPAR would 
block DHPG-induced GluR2 endocytosis. To test this empirically, mature hippocampal 
cultures (DIV 15-18) were treated  with 100 μM of DHPG and the surface GluR2 was 
evaluated 15 minutes post stimulation (Figure 3.6 A and B). Surprisingly, a modest but 
significant loss of GluR2 from the postsynaptic membrane was observed in both 
genotypes (Ube3a m+/p+: n=23 cells, 91 % ± 1.3 of NT controls, ***p<0.001; n=20 cells, 
93 % ± 1.9 of NT controls, *p<0.05). Our data suggests that while Ube3a loss influences 
the total and surface levels of AMPAR, it does not affect the mGluR-mediated GluR2 
trafficking. 
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3.5 Discussion 
LTP and LTD are forms of experience-driven synaptic plasticity. Despite using 
distinct molecular and cellular mechanisms, neuronal potentiation and depression co-
exist in the brain (Oliet et al. 1997; Bolshakov et al. 2000). Similar molecular 
mechanisms underlying LTP may also be involved in the mechanisms underlying 
hippocampal-dependent learning and memory formation (Lynch 2004). However, a 
behavioral correlate to  the actions and mechanisms controlling LTD remain elusive 
(Mukherjee and Manahan-Vaughan 2013). It is postulated that the balance between both 
forms of synaptic plasticity is the foundation for healthy neuronal physiology. Thus, 
human disorders with an associated cognitive defect may be caused by slight alterations 
in signaling cascades that result in alterations in either LTP or LTD 
The data presented here demonstrate that Ube3a m-/p+ animals display 
pronounced LTD deficit in both NMDAR-dependent and NMDAR-independent forms in 
the hippocampus. The observed reduction in NMDAR-LTD is not surprising and 
consistent with the previous report of a decrease in LTD magnitude in the neocortex of 
young and adult Ube3a m-/p+ animals (Yashiro et al. 2009). It is well established that 
NMDAR-induced LTD relies on the activation of phosphatases, PP1 and calcineurin, to 
modulate a wide variety of proteins involved in LTD propagation (Mulkey et al. 1993; 
Kirkwood and Bear 1994; Mulkey et al. 1994). Additionally, CaMKII phosphorylation is 
cited as one of the potential regulatory mechanisms of glutamatergic synaptic 
depression (Schnabel et al. 1999; Mockett et al. 2011). Ube3a m-/p+ mutant mice  
appeared to have deficits in both, PP1 activity and CaMKII autophosphorylation that 
could partially explain the NMDAR-LTD phenotype (Weeber et al. 2003). 
These studies also find that Ube3a is also involved in LTD elicited via Group I 
mGluRs. In hippocampal slices, PP-LFS or a brief application of a selective mGluR 1/5 
agonist failed to induce a similar LTD response in AS animals when compared to the 
65 
 
wild type controls.  It is well established that mGluR-LTD depends on the rapid protein 
synthesis initiated by several intracellular signal transduction pathways including PI3K 
and MAPK signaling cascades (Gallagher et al. 2004; Hou and Klann 2004; Banko et al. 
2006). Interestingly, we have recently reported that ERK levels are unaltered in the adult 
AS mouse; however, there are significant decreases in ERK activation following synaptic 
depolarization and fear conditioning (Filonova et al. 2014). Interestingly, we find no such 
alteration in ERK activation during depressive stimulation suggesting that this pathway is 
not affected by the absence of Ube3a as we observe no changes in basal kinase 
expression, phosphorylation or DHPG-induced activation. 
Redistribution of AMPA receptors is the ultimate driving force of synaptic 
transmission (Malinow and Malenka 2002; Song and Huganir 2002; Kessels and 
Malinow 2009). Synaptic depression is facilitated by the reduction of post-synaptic 
AMPA receptor subunits. In addition, rapid protein translation leads to up-regulation of 
several LTD-related proteins required for activity-dependent AMPA receptor trafficking 
(Waung and Huber 2009). One such protein is Arc, which is shown to be up-regulated in 
the AS mouse model (Greer et al. 2010). It is unclear whether Arc is an immediate 
Ube3a substrate (Kühnle et al. 2013); however, we also observe increased levels of Arc 
protein in area CA1 of Ube3a m-/p+ hippocampal slices. Furthermore, using receptor 
biotinylation and immunocytochemistry, we find a significantly reduced surface and 
increased internal dendritic GluR2 expression in Ube3a m-/p+ hippocampus. This 
observation is without a concurrent change in mGluR1/5 trafficking, indicating that the  
initially compromised AMPA receptor distribution, but not aberrant receptor trafficking, 
may underlie the deficit in mGluR-LTD. 
Numerous studies report that Ube3a negatively impacts LTP and subsequently 
disrupts learning and memory. We previously reported that saturating amounts of high 
frequency stimulation results in synaptic plasticity equal to that in litter mate controls 
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(Weeber et al. 2003). This suggests the capacity for plasticity in the hippocampus is 
intact and the LTP defect induced with a standard 100Hz, two-train stimulation, is not 
occluded. In other words, the measured synaptic activity is not already in a heightened 
state of synaptic plasticity and ceiling effect for increased plasticity reveals itself as an 
LTP defect. The results shown here suggest that the hippocampus of Ube3a m-/p+ mice 
show an occlusion of LTD. If we consider that the total amount of plasticity, either toward 
potentiation or depression, capable in area CA1 of Ube3a m-/p+ mice is equal to that of 
littermate controls, then the increased Arc and subsequent decreased AMPAR would 
have Ube3a m-/p+ mice starting at a base line already toward depression (Figure 3.7).  
In conclusion, expanding our knowledge and studying Ube3a outside the context 
of AS could not only prominently advance our understanding of this protein, but also 
open a window of opportunities for finding potential therapeutics that are used to treat 
other disorder to alleviate the severe cognitive symptoms associated with  the AS 
patients. 
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Figure 3.1 NMDAR-dependent LTD is impaired in AS mouse model. A and B. 
NMDAR-LTD was induced by paired-pulse low frequency stimulation (PP-LFS) in Ube3a 
m-/p+ (n=8, 4 animals) and Ube3a m+/p+ (n=9, 4 animals). Significant reduction was 
observed during last 30 min of LTD recording (Student‘s t-test, *p<0.05).  
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Figure 3.2. Ube3a m-/p+ animals show a deficit in mGluR-dependent LTD. A and B. 
PP-LFS was delivered to hippocampal slices in the presence of 50 µM D-AP5 to induce 
mGluR-dependent LTD. The induction of LTD (first 10 min) was not altered in Ube3a m-
/p+ (n=8, 4 animals) mice compared to Ube3a m+/p+ (n=10, 4 animals); however, the 
analysis of the 10-40 min post stimulation time interval revealed a significant reduction in 
fEPSP slope of Ube3a m+/p+ animals. C and D. mGluR-LTD was induced by a brief (5 
min) application of 100 µM DHPG, a selective mGluR 1/5 agonist, in Ube3a m-/p+ 
(n=13, 4 animals) and Ube3a m+/p+ (n=12, 5 animals) mice. Significant reduction was 
observed during last 30 min of LTD recording (Student‘s t-test, *p<0.05). 
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Figure 3.3. mGluR-ERK 1/2 and mGluR-mTOR pathways are in the CA1 area of 
Ube3a m-/p+ hippocampal slices.  A. Representative immunoblot of basal 
expression of ERK 1/2, mTOR, MAPK p-38 (p38) kinases and their phosphorylated 
states (p-ERK 1/2, p-mTOR, p-p38). Ube3a is used to indicate genotypes. C.  
Constitutive levels of ERK 1/2, mTOR and and p38 are unchanged between the 
genotypes (n=12 slices, 4 animals). Total protein levels are normalized to actin and 
standardized to Ube3a m+/p+ controls (n=8 slices, 4 animals). B, D and E. mGluR-
triggered ERK 1/2 and mTOR activation appears to be normal in the CA1 of Ube3a 
m-/p+. Only Arc protein was statistically increased in Ube3a m-/p+ mice. (Student t-
test, One-way-ANOVA were used when appropriate; ***p<0.001, *p<0.05). 
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Figure 3.4 Arc levels are elevated in the CA1 area of Ube3a m-/p+ hippocampal 
slices.  A. mGlur1/5-triggered signal transduction pathways (Gladding, 2009). B. Basal 
Arc expression is increased in CA1 of Ube3a m-/p+ animals (n=12 slices, 4 animals). 
Total protein levels are normalized to actin and standardized to Ube3a m+/p+ controls 
(n=8 slices, 4 animals). C. Arc protein is statistically increased in Ube3a m-/p+ mice 
followed a brief 100 μM DHPG application. (Student t-test, One-way-ANOVA were used 
when appropriate;  *p<0.05). 
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Figure 3.5.  Loss of Ube3a lead to altered GluR2 surface and internalized 
expression. A. Representative immunoblot. B. Surface biotinylation method was used to 
measure the surface expression. Quantitative Western blot analysis shows significant 
decrease in total and surface GluR2 levels but not in NR2B in Ube3a m-/p+ (n=7 slices, 3 
animals) compared to Ube3a m+/p+ littermate controls (n=7 slices, 3 animals). C and D. 
Ube3a loss leads to an increased amount of internalized GluR2 AMPAR subunit in 
dendrites. Scale bar – 20 μm. (Ube3a m+/p+: n=15 cells; Ube3a m-/p+: n=15 cells; s- 
surface, t-total, Student t-test, *p<0.05, **p<0.01). 
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Figure 3.6. Ube3a is not required for DHPG-induced GluR2 endocytosis. A. 
mGluR1/5 was activated by the application of 100 μM DHPG to induce AMPAR 
internalization. Surface GluR2 was visualized by immunocytochemistry. B. 
Immunoflourescence analysis of GluR2 intensity detected no difference in GluR2 
trafficking between Ube3a m-/p+ (n=20 cells) and Ube3a m+/p+ (n=23 cells) mature 
hippocampal cultures. (One-Way-ANOVA, *p<0.05, ***p<0.001). 
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Figure 3.7. Altered basal state of the synapses results the inability of induce LTD 
or LTP. Illustration of the potential for hippocampal plasticity for wild type (black) and AS 
animals (red). AS mice have a non-stimulation base line potential below that of wild type 
mice. This results in a lower percentage of DHPG- and low frequency stimulation-induced 
LTD. High frequency stimulation (HFS) also results in a lower percentage increase 
compared to wild type mice. Saturating high frequency stimulation (sHFS) results in the 
same maximum amount of potentiation as wild types, but occurs with a greater 
percentage increase between HFS and sHFS. 
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CHAPTER 4: THE ROLE OF UBE3A IN FXS PATHOLOGY 
 
4.1 Abstract 
Substantial evidence suggests that the loss of Ube3a alters activity–dependent 
signal transduction, which may ultimately result in impaired synaptic plasticity and 
cognition. Similar to AS, abnormal molecular and behavioral phenotypes have been 
observed in other mouse models of human mental retardation such as Fragile X Mental 
Syndrome (FXS). Analogous to Ube3a deficient mice, Fmr1 KO mice exhibit learning 
and memory deficits following contextual and trace fear conditioning which are paralleled 
by cellular changes such as increased Arc expression and abnormal AMPAR 
distribution. These data suggest that Ube3a and FMRP may belong to a similar signaling 
pathway.  In this work, we sought to explore if any of deviations in neuronal functioning 
caused by FMRP loss-of-function could be due to the abnormal Ube3a expression. 
Analysis of crude synaptoneurosomes of adult Fmr1 KO mice revealed a significant 
reduction in Ube3a protein as well as blunted local translation of Ube3a following 
mGluR1/5 stimulation. However, no evidence of direct association of Ube3a mRNA and 
FMRP was found. To examine if some of the pathology seen in Fmr1 KO mice might 
originate from Ube3a down-regulation, we performed a rescue experiment by increasing 
Ube3a expression in the hippocampus of Fmr1 KO mice via AAV-mediated delivery. An 
exhaustive battery of behavior testing revealed no significant effect of Ube3a on major 
abnormal behaviors of the Fmr1 KO mice, with the exception of worsening already 
impaired associative fear conditioning. These results suggest that while diminished level 
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of Ube3a may contribute to subtle phenotypes observed in FMRP deficient mice, it is not 
solely responsible for the FXS neuropathology.  
 
4.2 Introduction 
Autism spectrum disorder (ASD) comprise a family of developmental disorders  
characterized by impaired social interaction and communication, stereotyped behaviors, 
restricted interests, intellectual disabilities and often seizures (Tuchman and Rapin 2002; 
Baird et al. 2006). The prevalence of ASD has been rising alarmingly over the last 
decade (Wing and Potter 2002; Kogan et al. 2009; Matson and Kozlowski 2011). 
Currently, almost 1:100 children who exhibit some of the warning signs are diagnosed 
with ASD (Baird et al. 2006). A complex interaction of multiple genes and environmental 
factors are thought to give rise to ASD (Abrahams and Geschwind 2008). The 
complicated genetic aetiology creates an obstacle for identifying specific molecular 
mechanisms that underlie the symptoms. There are several neurodevelopmental 
disorders with high penetrance of autistic features such as Rett Syndrome, FXS (FXS) 
and AS that allow dissecting out specific dysfunctional cellular processes present in the 
disorder spectrum. The phenotypical overlap between these syndromes suggests that 
the independent ASD candidate genes may occupy convergent molecular pathways. 
FXS is the most common form of mental retardation (1:4000 males, 1:8000 
females) with highly variable symptoms (Barth et al. 2004). Intellectual disability, speech 
impairment, and abnormal social and emotional interactions are frequently observed in 
FXS individuals (Hagerman and Hagerman 2002). Approximately 4% of the ASD 
population has FXS related mutations indicating that anomalous molecular changes that 
exist in FXS are also present in patients with autism (Rogers et al. 2001; Volkmar et al. 
2005; Clifford et al. 2007). Most FXS cases originate from the hyper-expansion and 
methylation of CGG repeats within the promoter of FMR1 gene (Fu et al. 1991; Verkerk 
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et al. 1991). FMR1 codes for fragile X mental retardation protein (FMRP), an mRNA 
binding protein that is involved in activity-dependent translation (O'Donnell and Warren 
2002). The loss of FMRP function leads to exaggerated translation (Qin et al. 2005; 
Osterweil et al. 2010) culminating in abnormal spine morphology and number (Comery 
et al. 1997; Irwin et al. 2000), defective synaptic plasticity (Mercaldo et al. 2009) and 
poor cognition (Mineur et al. 2002; Zhao et al. 2005) . About 30% of the post-synaptic 
neuronal mRNAs are thought to be regulated by FMRP (Darnell et al. 2011). 
Interestingly, several FMRP targets such as CamKII α (Zalfa et al. 2003; Hou et al. 2006; 
Muddashetty et al. 2007), Arc (Bassell and Warren 2008; Niere et al. 2012), PSD 95 
(Todd et al. 2003) and GluR1 (Muddashetty et al. 2007) have also been implicated in AS 
neuropathology (Weeber et al. 2003; Greer et al. 2010).  Despite the distinct molecular 
dysregulations responsible for these disorders some common symptomology is 
observed between FXS and AS conditions in humans and mice (Table 1.1 and Table 
4.1). For example, both Fmr1 KO and Ube3a m-/p+ transgenic animals have audiogenic 
seizures and deficits in trace and contextual fear conditioning (Jiang et al. 1998; Zhao et 
al. 2005; Huang et al. 2013). Moreover, increased Arc expression, alterations in AMPAR 
distribution perturb regulation of CaMKII function may result from the loss of either 
Ube3a or FMRP. These evidences suggest that Ube3a and FMRP may belong to a 
convergent pathway important for learning and memory formation. A recent analysis of 
discrete mRNA sequences that serve as a recognition sites for FMRP binding uncovered 
almost 100 ASD-related genes. Electrophoretic mobility shift assays, microassay chip 
and immunobloting were used to validate some of the novel FMRP targets including but 
not limited to Ube3a and Sacsin (Ascano et al. 2012). This study was the first to propose 
a potential molecular link between AS and FXS; however, more experimentation is 
needed to establish a true connection. 
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In this work we sought to elucidate if any of the cognitive deficits found in Fmr1 
KO mice could be due to the alteration in Ube3a expression. We discovered a reduction 
in synaptic Ube3a protein in the hippocampus of adult Fmr1 KOs. We utilized  Ube3a-
AAV virus to deliver wild type Ube3a to the hippocampus of Fmr1 KO animals in order to 
counteract the deficit in protein. A battery of behavioral testing showed that the addition 
of exogenous Ube3a exacerbated the cognitive phenotype in this transgenic mouse 
model. Overall, the data suggest that diminished level of Ube3a may contribute to the 
FXS neuropathology. 
 
4.3 Material and methods 
4.3.1 Animals: All animals used in the study were handled in accordance with protocols 
approved by the Institutional Animal Care and Use Committee of the University of South 
Florida. Animals of either sex were group housed in a standard 12 hour light/dark cycle 
and fed standard mouse chow ad libitum. Due to the X-link genetic FXS transmission, 
only 3-4 months old Fmr1 KO males (FVB/129 SV mixed background) were used in 
behavioral and biochemical assessments. 
4.3.2 AAV-injections: Ube3a–AAV and GFP-AAV constructs were previously described 
(Daily et al. 2011). Mice were anesthetized and placed in the stereotaxic apparatus 
(51725D Digital Just for Mice Stereotaxic Instrument, Stoelting, Wood Dale, IL). The 
following coordinates were used to locate hippocampus: AP -2.7 mm, L ±2.7 mm, and V 
-3.0 mm. The Ube3a-AAV (1.5×1012 genomes/mL; n=8) or GFP-AAV (1.4×1012 
genomes/mL; n=8) was delivered bilaterally via intrahippocampal injections using a 10 
µL Hamilton syringe. Recombinant viral vectors in 1µL volume were co-administered 
with 1 µL of 20% mannitol in each hemisphere. Singly housed mice were allowed 5 
weeks recovery before the behavioral testing. 
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4.3.3 Behavioral testing: 
Elevated Plus Maze (EPM): The elevated plus maze (Stoelting, cat: 60140) was used to 
assess anxiety. The EPM apparatus consisted of two enclosed and two well-lit open 
arms that represented safe and fearful areas respectively. Each mouse was placed in 
the center of the elevated plus maze and allowed 5 minutes of free exploration. Video 
tracking software (Anymaze, Stielting) recorded mouse behavior and measured total 
distance travelled, time immobile, time spent in each arm and total entries to open arms. 
Open Field: Open field test was used to evaluate the animal‘s locomotor activity and 
anxiety related behavior. Each mouse was placed in a box (40cm X 40 cm X 35 cm) and 
allowed free exploration for 15 minutes. A moderate lighting was used above an open 
field box as well as white noise to provide an even background. During the test, multiple 
parameters (distance travelled, time spent in center and number of animal entries into a 
center zone) were measured by video tracking software (ANY-maze). 
Hidden platform water maze: The Morris Water Maze (MWM) was used to determine 
spatial memory. A 1.2 m diameter pool was filled with white opaque water. A 10 cm 
diameter white platform was submerged just below the water surface and large extra-
maze cues positioned around the room. Animals were placed in the pool and allowed to 
swim to the platform for a maximum of 60 seconds. The training paradigm consisted of 4 
trials/day for 4 days. Latency to escape and swim speed were measured by video 
tracking software (ANY-Maze). On the 5th day, the platform was removed and a 60 
seconds probe test was conducted.  
Contextual Fear Conditioning: Fear conditioning was used to assess learning and 
memory formation. On the day of training, animals were placed in a sound attenuated 
chamber for 3 minutes. Then, a 30 second acoustic conditioned stimulus (70 dB sound) 
was delivered with a 0.5-mA shock applied to the floor grid during the last 2 seconds of 
the conditioned stimulus. Training consisted of two mild shocks paired with two 
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conditioned stimuli with a 1.5 minute interval between each shock. For contextual 
memory, the mice were placed in the same chamber 24 hours later and monitored for 3 
minutes. Freezing behavior (2 seconds motionless position) was measured and percent 
of time spent freezing was calculated. 
Marble Burying Test: Marble burying test was used to evaluate anxiety, neophobia and 
compulsive behaviors. A plastic cage (30cmX50cm) was filled with softwood bedding 
(different from the regular home cage bedding). The surface was flattered and 15 glass 
marbles were positioned evenly throughout the cage. The animal was placed in the cage 
and allowed to explore for 30 minutes. After the animal was removed, the buried marbles 
(2/3 covered with the bedding) were counted.  
Social Interaction: Social interaction test was performed as previously described with 
some modifications (Moy et al. 2004; Nadler et al. 2004). In short, the experimental 
mouse was placed in the test cage and, after a 10 minutes habituation period (trial 1), a 
new mouse was added to one side of the apparatus. The interaction between the test 
mouse and the novel mouse was videotaped for 10 minutes (trial 2). The percent of time 
spent in a quadrant with the novel mouse (social quadrant) was calculated using ANY-
maze software. 
4.4.4 Synaptoneurosome isolation: Crude synaptoneurosomes were prepared as 
previously described (Villasana et al. 2006). Briefly, hippocampal tissue dissected from 
adult Fmr1 KO (3-4 months) and wild type littermate brains was homogenized in 2 mL 
dounce homogenizer with pestle A (5 strokes) and pestle B (5 strockes) in buffer 
containing 10 mM HEPES, 1 mM EDTA, 2 mM EGTA, 0.5 mM DTT, protease and 
phosphatase inhibitors. Samples were filtered 2 times through a 100 μm pore nylon filter 
(Millipore) and 1 time through a 5 μm pore nylon filter using 5 mL Luer Lock syringe. 
Some of the sample was set aside for the crude lysates analysis. The remaining filtrate 
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was centrifuged at 1000g for 10 min at 4ºC. The pellet containing crude 
synaptoneurosomes was resuspended in 0.32 M sucrose and 1 mM NaHCO3 (pH 7.0). 
The sample concentration was determined with the BCA assay and stored at -80 ºC until 
further processing. 
4.4.5 Synaptoneurosomal stimulation. The procedure was done as previously reported 
(Muddashetty et al. 2007). Cortical tissue was isolated from 3-4 months old wild type and 
Fmr1 KO mice. Synaptoneurosomes were prepared as described above but using a 
different homogenizing buffer: 118 mM NaCl, 4.7 mM  KCl, 1.2 mM MgSO4, 2.5 mM 
CaCl2, 1.53 mM KH2PO4, 212.7 mM glucose, and 1 mM DTT, pH 7.4, supplemented 
with protease inhibitors, 30 U/ml human placental RNase inhibitor and 200 g/ml 
chloramphenicol (Sigma, St. Louis, MO). After the centrifugation step, the pellets were 
resuspended in the same buffer to 1 µg/μl. Triplicate samples (60µl volume) were 
incubated for 15 minutes at 37ºC in the presence of a vehicle or 1 mM MCPG before the 
addition of 30 µM DHPG for 30 min. At the end of the experiment, samples were frozen 
with dry ice and stored in -80ºC until western blot analysis. 
4.4.6 Western Blot: Frozen tissue was homogenized by sonication in ice-cold RIPA 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 0.5% sodium 
deoxycholate, 1% triton X100) containing Halt protease and phosphatase inhibitors 
cocktails. The lysates were clarified at 14,000 g for 15 minutes. The protein 
concentrations were determined using the BCA Protein Analysis Kit (Pierce, Rockford, 
IL). Samples were resolved by 10% TGX gels (Bio-Rad) and transferred to PVDF 
membrane.  Membranes were blocked with 5% milk in TBST (50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, and 0.05% Tween-20) for 1 hour and incubated with primary antibodies at 
4ºC overnight or 1 hour at room temperature. After 3 10 minutes washes with TBST, 
secondary antibodies were applied for 1 hour at room temperature. Blots were detected 
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with film for chemiluminescence using Pierce ECL. Developed images were analyzed 
using ImageJ software. Antibodies: Ube3a (Bethyl BioLabs), PSD 95 (Neuromab), 
FMRP (Millipore), β-tubulin (Cell Signaling).   
4.4.7 Non-fluorescent immunohistochemistry: Mice were transcardially-perfused with 
saline solution (0.9% NaCl in water). Removed brains were placed in 4% PFA diluted in 
0.1M PBS and dehydrated via sucrose gradient (10%, 20%, 30%) and sectioned on a 
microtome at 30 μm. Free-floating sections were blocked in 4% goat serum, 0.2% lysine 
in 0.1M PBS and incubated with Ube3a primary antibody overnight (1:1000). Secondary 
antibodies were added for 2 hours and the avidin-bionit-HRP complex was formed with 
VECTASTAIN® ABC kit (Vector labs). DAB was used to develop the stain. Sections 
were imaged with a Zeiss Mirax Scan 150 microscope. Identification of positive staining 
and percent area of positive stain was performed using Image Analysis software 
(created by Andrew Lesniak, Zeiss). 
4.4.8 Statistical analysis: One-way ANOVA (Tukey‘s post hoc test) or Student t-test was 
applied when appropriate using Graph Pad Prism 5.01 (La Jolla, CA).  
 
4.4 Results 
4.4.1 Synaptic Ube3a expression is decreased in the hippocampus of adult Fmr1 KO 
mice 
Ube3a is ubiquitously expressed throughout the neuron. It is also present in the 
synaptoneurosomes and PSD fraction (Dindot et al. 2008; Gustin et al. 2010). Our early 
results demonstrated that Ube3a expression is crucial for the mGluR1/5-dependent LTD 
(Chapter 3), a form of synaptic plasticity that heavily relies on local protein synthesis and 
that is under the control of FMRP repressor protein. Additionally, the observations that 
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both AS and FXS share some common features led us to hypothesize that some of the 
FXS pathology might be due to the alterations in Ube3a expression.  To address this 
question, we examined total Ube3a levels in the hippocampus of adult Fmr1 KO mice via 
immunochistochemistry (3-4 months old, n=8 per genotype). We detected no differences 
in Ube3a staining between Fmr1 KO and the littermate controls (Figure 4.1 A and B). 
Data shows that FMRP is localized to the dendrites where it regulates translation of a 
specific group of proteins. Therefore, we utilized a subcellular fractionation technique to 
study Ube3a expression in isolated crude synaptoneurosomes. The filtration method 
allowed us to obtain fairly pure synaptoneurosomes as we found an enrichment of PSD 
95 and synaptophysin in the synaptoneurosomal fraction compared to the crude lysates 
(Figure 4.2 A). Using western blotting, we found a significant reduction in synaptic 
Ube3a expression in Fmr1 KO mice (64.43 % ± 7.630 of WT controls, n=4) compared to 
the wild type controls (100% ± 7.872, n=5). Consistent with previous publications, 
(Muddashetty et al. 2007), we also detected a reduction in PSD 95 and GluR1 proteins.  
(PSD 95, 59.44 % ± 7.191; GluR1, 59.21 % ± 5.012 of WT controls). FMRP antibody 
served as a positive control for correct genotyping (Figure 4.1 C and D).  The changes 
detected in Ube3a suggest a possibility of an interaction between these two proteins. 
4.4.2 Synaptic Ube3a expression induced by mGluR1/5 stimulation is blunted in Fmr1 
KO mice 
It has been widely accepted that the null mutation of Fmr1 leads to the enhanced 
mGluR-LTD suggesting that FMRP is crucial for the mGluR signaling (Huber et al. 2002; 
Koekkoek et al. 2005; Hou et al. 2006). Several FMRP targets such as PSD 95 
(Muddashetty et al. 2007), Arc (Niere et al. 2012) and STEP (Zhang et al. 2008) show an 
increase in local protein synthesis in response to mGluR1/5 activation by DHPG. To test 
if Ube3a is also subjected to similar regulation, we stimulated crude synaptoneurosomes 
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isolated from the wild type cortex with 30 μM DHPG for 5 min, 30 min and 45 min and 
used western blotting to determine Ube3a levels. We observed a significant increase in 
Ube3a (157.9 % ± 11.40 of NT controls, n=8) as well as PSD 95 (136.1% ± 9.682 of NT 
controls, n=6) following by 30 minutes DHPG application. Tubulin expression was not 
affected. To ensure that the increase in protein levels was due to the mGluR1/5 
activation, we pretreated synaptoneurosomes with 1 mM of MCPG, a mGluR antagonist. 
No significant changes in neither Ube3a nor PSD 95 were detected in MCPG-treated 
samples (Ube3a, 120% ± 11.55; PSD 95, 105.7% ± 4.655 of NT controls, n=3) indicating 
that the observed elevation in Ube3a and PSD 95 is mGluR1/5 specific. Next, we 
investigated if increase in Ube3a following mGluR1/5 stimulation is intact in the FMRP 
deficient mice. Thus, we performed synaptoneurosomal stimulation in the cortex of Fmr1 
KO transgenic littermates. The previously observed increase in Ube3a protein in 
response to DHPG application was abolished in FMR1 KO cortical synaptoneurosomes. 
These results provided more evidence for the potential regulation of Ube3a by FMRP.  
Finally, we proceeded to determine if Ube3a mRNA directly binds FMRP protein by 
performing direct FMRP IP and subsequent RNA analysis. We did not find an interaction 
between FMRP and Ube3a mRNA suggesting that the decrease in Ube3a expression in 
Fmr1 KO mice is a product of other molecular abnormalities cause by the FMRP loss.  
4.4.3. Increase in exogenous Ube3a protein exacerbates behavioral phenotype of Fmr1 
KO mice  
 Fmr1 KOs exhibit a variety of abnormal behaviors such as increased anxiety 
(Spencer et al. 2005), aberrant social interaction (Mineur et al. 2006; McNaughton et al. 
2008), hyperactivity (Mineur et al. 2002) and decreased freezing rates in contextual and 
trace fear conditioning tests (Paradee et al. 1999; Zhao et al. 2005). Despite the 
absence of the direct interaction between FMRP and Ube3a, we hypothesized that 
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Ube3a might partially contribute to the neuropathology seen in Fmr1 KO mice. To test 
this, we increased Ube3a expression via AAV-mediated delivery of exogenous Ube3a, 
which we have previously shown to ameliorate synaptic and behavioral deficits in the AS 
mouse model (Daily et al. 2011). Then, we investigated if any of the abnormal 
phenotypes could be rescued by the increase of wild type Ube3a to the hippocampus of 
Fmr1 KOs.  
To determine the effect of the increased Ube3a on the Fmr1 KO behavior 
phenotype, we injected adult (3-4 month old) FMRP deficient males with Ube3a-AAV or 
GFP-AAV control vector and conducted a battery of behavioral tests 5 weeks following 
the injection. To start with, we examined the anxiety-related behaviors by subjecting 
mice to the elevated plus maze test (EPM). No difference was observed in time spent in 
the open arms when comparing either genotypes or experimental groups (Fmr1 KO + 
Ube3a-AAV and Fmr1 KO + GFP-AAV). However, we detected statistically significant 
genotypic difference between wild type (19.24 ± 2.669, n=7, *p>0.05) and Fmr1 KO + 
GFP-AAV (7.138 ± 1.772) in immobile time but not between Fmr1 KO + Ube3a-AAV 
(Figure 4.3 A-C). These data demonstrate that increasing Ube3a expression does not 
affect anxiety in Fmr1 KO mice. 
Next, the general activity and locomotor behavior was evaluated by 15 minute 
exposure to an open field. In accordance with previous publications, we found a 
significant increase in distance traveled in both experimental groups (Fmr1 KO + Ube3a-
AAV, 40.38 ± 1.217; Fmr1 KO + GFP-AAV, 39.33 ± 3.144, **p>0.01) compared to WT 
controls (26.60 ± 2.770) (Figure 4.4 A). Analysis of center entries didn‘t indicate any 
dissimilarity between the groups; however, a trend toward increased center occupancy 
was observed in Fmr1 KO + Ube3a-AAV animals (Figure 4.4 B and C). Additionally, a 
social interaction test and a marble burying test were used to examine social deficits and 
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compulsive behaviors and neophobia, respectively. All the groups performed evenly well 
on both tasks (Figure 4.6 A-B). 
Spatial learning and memory was tested by using the hidden platform water 
maze test. All the groups were trained for 4 days (4 trials a day) to find the hidden 
platform. The latencies to reach the platform were similar in all the animals indicating 
comparable to the wild type memory acquisition in Fmr1 KO + Ube3a-AAV and Fmr1 KO 
+ GFP-AAV groups. A 60 second probe trial was conducted on the 5th day of testing 
revealed no difference in the time spent in the target quadrant, suggesting that all the 
animals could equally remember the location of the escape platform. The occupancy 
plots indicate the utilization of similar strategies by all groups (Figure 4.5 B and C). 
A separate hippocampus-dependent task, contextual fear conditioning, was used 
to evaluate learning and memory through freezing behavior in the context 24 hours after 
training. Fmr1 KO + Ube3a-AAV (6.619 % ± 1.192 of total time freezing, ***p>0.001) and 
Fmr1 KO + GFP-AAV (14.10% ± 2.471, p>0.01) animals showed significantly lower 
freezing rates compared to the wild type (32.31 % ± 4.551) (Figure 4.5 A). Interestingly, 
a significant reduction was detected in Fmr1 KO injected with Ube3a-AAV compared to 
the Fmr1 KO + GFP-AAV suggesting that the increase in Ube3a negatively influenced 
contextual fear memory. 
4.4.4 Ube3a-AAV expression in Ube3a m-/p+ and Fmr1 KO 
Initially, we tested the efficacy of the viral delivery, distribution and the ability to 
express the protein of Ube3a-AAV construct in Ube3a m-/p+ (Daily et al. 2011). This 
mouse model produces small (approximately 5% of total) paternal Ube3a allowing for 
easy differentiation between endogenous vs exogenous Ube3a expression. Ube3a m-
/p+ mice were injected intrahippocampally with either Ube3a-AAV (n=4) and GFP-AAV 
(n=3) and were sacrificed 5 weeks post-surgery. Ube3a and GFP expressions were 
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assessed by immunohistochemistry (Figure 4.7 A). We observed an increase and wide 
distribution of Ube3a and GFP expression. Next, we examined the Ube3a-AAV 
expression in the Fmr1 KOs that were used in the behavior testing. We found that the 
Ube3a expression was statistically increased in Fmr1 KO+Ube3a-AAV group (n=4;145.2 
% ± 13.9 of the wild type, *p>0.05) compared to the control Fmr1 KO (n=4;93.07 % ± 8.4 
of the wild type ) (Figure 4.7 B and C). These data demonstrate that the Ube3a was 
successfully delivered and expressed in the hippocampus of Fmr1 KO mice suggesting 
that the observed change in the behavior was specific of the AAV-mediated Ube3a 
upregulation. 
 
4.5 Discussion 
Evidence connects FMRP to various forms of synaptic plasticity such as mGluR-
LTD, LTP priming and synaptic scaling that fully or partially relies on protein translation 
(Sidorov et al. 2013). The identification and analysis of FMRP targets became a 
necessary step in understanding the role and function of FMRP in the neuronal network. 
To date, over 800 RNAs that interact with FMRP have been isolated from the brain of 2 
week old animals. Interestingly, 23% of these RNA are located postsynaptically where 
they code for a variety of proteins especially the elements of NMDAR or mGluR 
intercoms (Darnell et al. 2011). An additional study that utilized high-throughput 
screening of distinct RNA-recognition elements that bind FMRP revealed that 
approximately 100 ASD-related genes that are also involved in Rett, Prader-Wili and 
Angelman syndromes (Ascano et al. 2012). This discovery emphasizes the possibility 
that molecules involved in these neurodevelopmental disorders ultimately belong to the 
same cellular pathways that are responsible for normal learning and memory.  
In the present study we determined if any connections exist between AS and 
FXS through the interaction of Ube3a and FMRP, respectively. We examined Ube3a in 
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synaptoneurosomes of Fmr1 KO mice and discovered a significant reduction in Ube3a 
expression. Moreover, we studied the DHPG-induced alteration of Ube3a in crude 
synaptoneurosomes isolated from the cortex of 3-4 month old wild type and transgenic 
littermates. Similarly to other FMRP targets such as Arc (Niere et al. 2012), PSD 95 
(Todd et al. 2003) and STEP (Zhang et al. 2008), we observed the mGluR1/5 specific 
Ube3a up-regulation in wild type samples at 30 minutes post DHPG application. On the 
contrary, DHPG failed to induce comparable changes in Ube3a in Fmr1 KO preparation 
suggesting that FMRP is required for mGluR1/5-dependent protein translation of 
synaptic Ube3a. However, the qRT-PCR analysis did not uncover a direct interaction 
between Ube3a mRNA and FMRP suggesting that Ube3a levels may not be directly 
mediated by FMRP. The identification of FMRP targets through a co-
immunoprecipitation has been a laborious task, the outcome of which greatly depends 
on the IP conditions. For example, a high concentration of monovalent cations can 
interfere with the RNA-protein interaction and/or produce non-specific results (Zalfa et al. 
2003; Iacoangeli et al. 2008). Nonetheless, this suggests a possibility that further 
optimization of IP conditions or utilization of younger animals could yield more positive 
results. Meanwhile, the decrease in Ube3a expression could be potentially explained by 
the impaired Ube3a trafficking to the dendrites or an abnormal Ube3a transcription 
caused by the alterations in one of the FMRP-dependent proteins. Future work that 
clarifies how FMRP regulates the levels of Ube3a, may prove critical to our 
understanding of both AS and FXS. 
The majority of research directed towards elucidating FMRP function has been 
conducted in the young (2 week old or 2 month old) FMRP deficient animals (Darnell 
and Klann 2013). Multiple studies suggest that the alteration in FMRP-bound RNA and 
protein expression depends on the brain region, age, and sometimes an animal‘s 
genetic background. For instance, PSD 95 and GluR1 protein expression show no 
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difference in the neocortex of 2 week old and 2 month old C57 Fmr1 KO (Schütt et al. 
2009), while PSD 95 was found to be significantly downregulated in the prefrontal cortex 
of 2-4 month old C57 FMRP deficient animals. The developmental examination of Ube3a 
mRNA and Ube3a protein in different cellular compartments in various brain regions 
could provide more insight into the specific dysregulation of this protein in Fmr1 KO 
animals and aid in understanding its involvement in the FXS pathology. 
 Our results show that the reduction in Ube3a protein in adult Fmr1 KO mice 
could be a compounding factor that underlies  FXS symptoms. Our laboratory previously 
demonstrated that the delivery of wild type Ube3a via AAV9 viral vector appeared to be 
beneficial as it rescued some of the synaptic plasticity and cognitive defects in Ube3a 
deficient mice (Daily et al. 2011). Utilizing a similar strategy, we sought to investigate if 
the increase in Ube3a could also normalize some of the cognitive deficits seen in FXS 
mouse model. We delivered the wild type Ube3a-AAV to the hippocampus of adult Fmr1 
KOs and assessed its effect through the behavioral output. The increase in wild type 
Ube3a did not result in any changes in overall locomotor behavior, anxiety or social 
interaction in Fmr1 KO injected with either Ube3-AAV or GFP control as they performed 
comparable to wild type on the tasks. However, we observed a significant decrease in 
freezing rates in the Fmr1 KO + Ube3a-AAV group when compared to  Fmr1 KO + GFP-
AAV controls suggesting that elevated Ube3a levels could be detrimental to cognition. 
Interestingly, no change in water maze performance was detected between experimental 
groups implying that an increase in Ube3a exacerbated already present deficits but did 
not affect normal hippocampal-dependent behavior.  
 Paternal Ube3a undergoes an energy-expensive complex epigenetic silencing in 
order to maintain an optimal dosage of Ube3a that is required for normal brain function. 
Any alteration in maternal Ube3a expression leads to abnormal changes in cellular 
biochemistry resulting in either AS or ASD. Ube3a deficient animals exhibit motor and 
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learning and memory impairments while a duplication Ube3a mouse model is 
characterized by an increase in  repetitive behavior and impaired social interaction. 
(Nakatani et al. 2009; Smith et al. 2011). The increase in Ube3a expression in the 
hippocampus of Fmr1 KOs via viral injection resembles the latter condition. Interestingly, 
we did not observe any changes in social behavior or marble burying tests. This could 
be explained by a targeted to hippocampus protein delivery. It is likely that more wide 
spread viral distribution is necessary to affect more complex behaviors. Nevertheless, 
the decrease in fear conditioning performance in Fmr1 KO + Ube3a-AAV group provides 
an additional support to the idea that optimal Ube3a expression is crucial for learning 
and memory processes. 
 In summary, Ube3a has already been implicated in development and aging; 
however, the study of Ube3a function in CNS has been limited to the AS mouse model.  
As we propose a more general role of Ube3a in the overall mechanisms for modulating 
synaptic efficacy and strength, we could only speculate if Ube3a could contribute to a 
variety of diseased states including but not limited to FXS. 
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Table 4.1 Summary of physiopathology in the AS and FXS mouse models. 
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Figure 4.1. Synaptic Ube3a is decreased in the hippocampus of Fmr1 KO mice. A 
and B. Immunohistological analysis revealed no change in total Ube3a expression in the 
hippocampus of 3-4 month old Fmr1 KO (n=8) and wild type littermates (n=8). C and D. 
Ube3a was significantly reduced in synaptoneurosomes isolated from hippocampus of 
adult Fmr1 KO (n=4) and wild type controls (n=5). PSD 95 and GluR1 expression was 
also decreased in the same sample. No change in tubulin (loading control) was 
detected. Anti-FMRP antibody was used to determine the correct genotype. (Student t-
test,  *p>0.05, ** p>0.01) 
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Figure 4.2. Synaptic Ube3a expression is upregulated in response to mGluR1/5 
stimulation in wild type but not in Fmr1 KO animals. A. The filtration methods used 
for synaptoneurosome preparation yielded fairly pure fractions as enrichment of PSD 95 
and Synaptophysin (SNF) was observed in crude synaptoneurosomal fraction (SNS) but 
not in the total homogenates (HOM). B. 30 μM DHPG was used to induce mGluR1/5 
activation in synaptoneurosomes isolated form cortex of adult wild type (n= 2 animals). A 
significant increase in Ube3a and PSD 95 was found in DHGP treated samples 30 
minutes post application (n=8) compared to the NT group (n=6). mGluR1/5 specificity 
was determined by blocking mGluR1/5 with 1 mM of MGPG. No differences were 
detected in Ube3a and PSD 95 in MCPG pre-treated samples (n=3). C. A similar 
experiment was conducted with Fmr1 KO (n=2 animals). DHPG failed to induce any 
changes in Ube3 expression (n=6). (One way ANOVA,  *p>0.05, ** p>0.01).  
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Figure 4.3. The increase in Ube3a expression in Fmr1 KO mice didn’t affect the 
anxiety behavior. Anxiety related behaviors were assessed by 5 minute elevated arm 
maze test. A. No difference in time spent in open arm (OA) between WT type (n=7) and 
Fmr1 KO injected with either Ube3a-AAV (n=8)  or GFP-AAV (m=8) was detected. B.  
Fmr1 KO + GFP-AAV mice showed a significant decrease in time spent immobile. C. 
Occupancy plots represent the combined movement of all the animals in a group (One 
way ANOVA,  *p>0.05). 
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Figure 4.4. The delivery of exogenous Ube3a to the hippocampus of Fmr1 KO mice 
didn’t influence the locomotor behavior. A 15 minute open field test was conducted to 
evaluate overall animal activity. A. Fmr1 KO injected with either Ube3a-AAV (n=8) or 
GFP-AAV (n=8) exhibit hyperactivity and showed significant increases in distance 
traveled compared to wild type control group (n=7). B. No statistically significant 
differences were observed between any of the groups in the time spent in the center. 
However, a trend was identified in Fmr1 KO + Ube3a-AAV mice (One way ANOVA,  
**p>0.01). C. Representative occupancy plots. 
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Figure 4.5. The associative but not spatial memory is affected by the increased 
Ube3a expression in Fmr1 KO mice. A. Contextual fear conditioning was used to test 
associative memory the 24 hour context test revealed a genotypic difference between 
wild type (n=7) and Fmr1 KO mice. Additionally, a statistical decrease in freezing rates 
was observed in Fmr1 KO animals injected with the Ube3a-AAV (n=8) compared to the 
GFP injected controls (n=8). B. All the groups perform equally well on the 24 hour 
probe trial in the hidden platform water maze test. C. Representative occupancy plots 
of the 60 second 24 hour probe trail in the water maze test. 
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Figure 4.6. No genotypic or treatment differences were detected in social 
interaction or marble burying tests. A. Marble burying test was conducted to assess 
anxiety, neophobia or compulsive behaviors. All the treatment groups performed 
ccomparable to the wild type. B. Social interaction evaluated by the Crowley social 
interaction test was normal among the animals (WT type (n=7); Fmr1 KO + Ube3a-AAV 
(n=8); Fmr1 KO + GFP-AAV (n=8). 
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Figure 4.7. Ube3a-AAV expression in Ube3a m-/p+ and Fmr1 KO mice.  Ube3a m-
/p+ animals were used to evaluate Ube3a-AAV expression. A. Ube3a-AAV (n=4) or 
GFP-AAV (n=3) control vector was injected into the hippocampus of Ube3a m-/p+ 
animals. The protein expression and distribution was determined 5 weeks post injection. 
B–C. Western blotting revealed an increase in AAV-mediated Ube3a expression in the 
hippocampus of Fmr1 KO mice (n=4) compared to GFP controls (n=4)(One way 
ANOVA, *p>0.05).  
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CHAPTER 5: DISSCUSSION 
 
“If our brains were simple enough for us to understand them, we’d be so 
simple that we couldn’t.” 
- Ian Stewart, The collapse of Chaos: Discovering Simplicity in a Complex 
World 
 
“The more I learn, the more I learn how little I know.” 
- Socrates 
 
For many years the molecular mechanisms underlying protein degradation 
remained a mystery until lysosomes and later the ubiquitin-proteasomal system (UPS) 
were discovered (De Duve et al. 1953; Ciehanover et al. 1978). Modern neuroscience 
now takes for granted an astonishing high rate of continuous protein synthesis and 
degradation that is required for adequate neuronal existence. The UPS is involved in a 
growing list of essential biological processes including, but not limited to, cell cycle, 
transcription and overall quality control of proteins in somatic cells as well as in neurons 
(Ciechanover 2005; Weissman et al. 2011). The mammalian brain is unique and 
complicated piece of machinery that constantly undergoes structural and compositional 
modifications in response to the sensory and emotional experiences. The neuronal 
activity drives synaptic remodeling to accommodate and support molecular changes 
required for long-lasting synaptic plasticity. The reorganization of synapses is 
accomplished by protein translation, transcription and degradation. It is not surprising 
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that a malfunction of one of the UPS components can disrupt normal neuronal 
functioning leading to a variety of overt symptoms. Thus, many neurodegenerative 
diseases such as Alzheimer‘s (Keller et al. 2000; Keck et al. 2003), Parkinson‘s (Kitada 
et al. 1998; Vila and Przedborski 2004) and Amyotrophic lateral sclerosis (Kabashi et al. 
2008) are linked to a dysfunctional protein clearance. Moreover, some autistic behavioral 
phenotypes are thought to originate from defective ASD-related genes that are involved 
in protein turnover (Baron et al. 2006; Lehman 2009). However, no other single protein 
demonstrates the importance of UPS proteins in cognition than Ube3a. A point mutation 
in a catalytic domain of Ube3a, an E3 substrate specific ligase, results in one of the most 
severe forms of mental retardation (Matsuura et al. 1997; Yamamoto et al. 1997). 
However, it is important to note that it remains unsubstantiated whether Ube3a-
dependent alterations in the UPS are ultimately responsible for the AS phenotype.     
Out present work was design to broaden the knowledge of Ube3a and its 
contribution to learning and memory. It has been well established that neuronal activity 
modulates protein composition. The increase in neuronal activity leads to the increase in 
the ubiquitin-conjugated proteins and subsequent activation of proteasome-regulated 
proteolysis as a mechanism for maintaining optimal protein levels and a compliment of 
functioning proteins (Ehlers 2003; Yi and Ehlers 2005; Bingol and Sheng 2011). Nearly 
all research of Ube3a in the mouse model established learning and memory defects, as 
well as synaptic dysfunction, but molecular pathways and protein alterations following 
neuronal activity or depolarization has not been well explored. Taking this into 
consideration, we sought to examine if Ube3a is subjected to similar regulation following 
synaptic activation via KCl depolarization and fear conditioning training. Our results 
demonstrated that like many other molecules, Ube3a is sensitive to change in neuronal 
activity. Recent publication already described an increase in total Ube3a protein 
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following the exposure to a novel environment (Greer et al. 2010); however, our study 
took one step further and examined the response of the paternal and maternal Ube3a to 
the fear conditioning training. We detected both elevated expression in maternal and 
paternal Ube3a starting 1 hour after the fear conditioning training. This data raises some 
of the important questions i) what modulates activity-dependent Ube3a increase and ii) 
what role the paternal Ube3a plays in the synaptic plasticity? 
The alterations of Ube3a could originate from a translation of pre-existing mRNA 
or from a newly transcribed gene. The 1-3 hour temporal increase suggests the latter 
situation. The analysis of DNA promoter region of Ube3a identified the presence of 
myocyte enhancer factor 2 (MEF2) binding site (Greer et al. 2010). The chromatin 
precipitation showed a direct interaction between MEF2 and isoform 1 and 3 of Ube3a.  
Moreover, the lentiviral injection with siRNA directed against MEF2A and MEF2D 
resulted in significant reduction of Ube3a protein, suggesting that Ube3a might be 
controlled by the MEF2-dependent gene regulation. Another protein MeCP2 could also 
be considered a potential candidate for Ube3a transcriptional regulation. Mutations in 
MeCP2 produce similar to AS symptoms implying a possible molecular association 
between these two proteins (Watson et al. 2001; Hitchins et al. 2004). To date, the 
connection between Ube3a and MeCP2 is controversial. Several publications reported 
either increase or decrease in Ube3a in MeCP2 KO animals (Makedonski et al. 2005; 
Samaco et al. 2005; Jordan and Francke 2006; Lawson-Yuen et al. 2007). The 
discrepancies could be attributed to the animal age and an experimental procedure; 
therefore, more data is needed to come to a more supported and solid conclusion. 
Despite the possibility that MEF2 or MeCP2 controls activity-dependent Ube3a 
transcription in wild type animals, it will be important to better understand if this is the 
same process that governs paternal Ube3a expression. This becomes a particularly 
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sensitive issue in light of the effort and progress to reactivate, or ―unsilence‖ the paternal 
allele as a therapeutic strategy in the treatment of human AS.   
Our observations of the increased paternal Ube3a in the hippocampus of Ube3a-
YFP mice following fear conditioning raises some critical issues about the paternal 
Ube3a. First, it was unclear if the slight protein seen in Ube3a m-/p+ mice or in the post 
mortem brains of AS patients was due to neuronal sources. In situ hybridization was 
inconclusive as to the source of paternal expression. Here we find that paternal Ube3a 
protein increases following fear conditioning; thus, at least some, if not all, of the 
detectable Ube3a from the paternal allele is neuronal if not synaptic. Second, the 
regulation of paternal expression following fear conditioning suggests a possible role for 
paternal Ube3a in normal neuronal function. Is this slight increase possible to have a 
role in learning and memory? This is a valid question since slight changes in Ube3a 
protein at the synapse may have a quite significant effect. This may already be 
supported by the evaluation of the severity of symptoms in AS patients. A small 
percentage of AS individuals who have two times normal paternal expression through 
uniparental paternal disomy (inheritance of two paternal alleles) or a methylation defect 
show a milder phenotype then deletion patients.  
One critical caveat to these studies exists in utilization of an Ube3a-YFP reporter 
animal. Specifically, the addition of the YPF tag to the C-terminus of Ube3a caused a 
significant reduction of the paternal Ube3a-YFP protein when compared to the paternal 
wild type Ube3a obtained from the maternal Ube3a-YFP crosses. The reasons for this 
reduction are not clear. The change in Ube3a protein conformation produced by the 
addition of YFP may lead to higher than normal protein degradation. Additionally, the 
alteration to Ube3a gene may interfere with the Ube3a transcription resulting in lower 
RNA production and protein translation. Nevertheless, the fact that the stringent 
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epigenetic control of paternal Ube3a protein can be overcome by neuronal activation is 
an exciting discovery. The biological mechanisms responsible for the activity-dependent 
increase in the paternal Ube3a are widely unknown. It is a possibility that alterations in 
transcription rates between pUbe3a and Ube3a-ATS are altered in a way allowing a 
small fraction of pUbe3a to undergo transcription. Alternatively, neuronal activity may 
lead to chromatin modification through a wide variety biochemical cascades; this, 
subsequently, could promote overall protein transcription including pUbe3a allele. In 
recent years a paternal Ube3a became a desired pharmacological target in AS research 
(Huang et al. 2011); however, many questions concerning a silent paternal allele, its 
distribution, isoform production and function should be addressed before considering it 
as a potential therapeutic. This pilot study nicely lays a foundation for additional 
investigation that would aim to expand our understanding of the paternal Ube3a in 
complex behaviors.  
Whole cell homogenates used in our experiments offered only a general idea of 
Ube3a expression in an activity-dependent context. In future, immunostaining of various 
brain regions would provide details as the precise location of Ube3a activation and 
paternal Ube3a expression origin (glial vs neuronal). Additionally, the degree of paternal 
Ube3a activation is important, considering that fear conditioning activates only a small 
number of neurons in the hippocampus (Strekalova et al. 2003; Huff et al. 2006). A 
transgenic mouse fos-GFP crossed with a Ube3a-YFP mutant could be utilized to 
investigate localization and expression of paternal or maternal Ube3a in active neurons 
during specific behavioral task (Barth et al. 2004). The study of the paternal Ube3a 
activated by neuronal activity might be instrumental in elucidating complex mechanisms 
underlying the imprinting. 
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In Chapter 2 we determined that activity-dependent ERK 2 phosphorylation is 
affected by the Ube3a disruption. Several kinases implicated in learning and memory 
has been previously examined in Ube3a deficient mouse model. Only alterations in 
CaMKII such as decreased activity and abnormal phosphorylation were found in the AS 
hippocampus at basal state (Weeber et al. 2003). Interestingly, the study failed to 
identify deficits in other kinases including ERK 1/2 providing an additional value to the 
activity-dependent approach. However, our initial ERK study needs further elaboration to 
determine specific molecular pathways that are responsible for the decreased ERK 
function. Chapter 3 shows normal ERK response to mGluR1/5 stimulation, suggesting 
that the alternation in ERK phosphorylation is signal transduction specific. It has been 
established that MEK 1/2 directly phosphorylates ERK1/2. Interestingly, our study didn‘t 
identify any changes in activity-dependent alterations in MEK phosphorylation. Abnormal 
ERK dephosphorylation or altered cellular ERK 1/2 distribution may partially explain this 
phenomenon. First, several phosphatases such as PP1 and PP2A has already been 
implicated in the pathology of AS. Taking this into consideration, it is a possibility that the 
activity-induced phosphorylation / dephosphorylation equilibrium has been compromised 
leading to the reduced ERK phosphorylation. Second, Ube3a loss could also result in 
the abnormal cellular ERK 1/2 distribution that could prevent or impede direct interaction 
between these two kinases. However, at the present time, more experimentation is 
needed to clarify these hypotheses. 
A variety of block and rescue experiments could be designed to dissect out a 
source of ERK pathology and analyze its effect on the downstream of ERK cellular 
cascades. This information may be critical and could provide some alternative 
explanation to the abnormal cognition seen in Ube3a m-/p+ mice. For example, 
ERK/MAPK pathway has been implicated in the regulation of gene induction through the 
histone modification in CA1 area of the hippocampus after fear conditioning (Chwang et 
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al. 2006). The abnormal activity-dependent gene transcription caused by a disrupted 
ERK activation may explain why AS mice have deficit in long term but not short-term 
memory. However, more investigation is needed to test this hypothesis. 
 In Chapter 3 we establish that the Ube3a m-/p+ mice exhibit reduced NMDA-
dependent and NMDA-independent LTD suggesting that Ube3a plays broader role in 
overall synaptic function and is required for both synaptic potentiation and depression. 
We hypothesized that the increase in immediate early gene Arc is likely a cause of the 
reduced mGluR-LTD. The relationship between Ube3a and Arc remains elusive. It has 
been shown that Ube3a does not directly ubiquitinate Arc but rather acts as its 
transcriptional activator (Greer et al. 2010; Kühnle et al. 2013). The lack of solid 
evidence about Ube3a and Arc interaction makes it more difficult to determine if 
abnormal Arc expression is exclusively responsible for the mGluR-LTD deficits observed 
in Ube3a m-/p+ mice. One way to clarify this is to create a Ube3a m-/p+ /Arc -/+ double 
knockout mouse. The rescue of the synaptic depression in the double mutants would 
indicate the Arc-dependent mGluR-LTD deficit. Alternately, no change in LTD 
expression would suggest that loss of Ube3a perturbs different molecular mechanisms 
controlling synaptic depression. The thorough examination of LTD signal transduction 
pathways will provide a more complete picture of Ube3a actions in the regulation the 
synaptic plasticity. 
Based on our results, we posit that increased Arc leads to an occlusion of LTD. 
In other words, the synapses of the Ube3a m-/p+ hippocampus are already in a 
depressed state. Thus, the amount of induced LTD is reduced compared to that in wild 
type mice and presents as an LTD deficit. This is supported by previous research 
showing that saturating HFS results in LTP equivalent to that in litter mate controls. This 
raises the interesting question of the importance of the LTD defect in the overall AS 
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mouse phenotype. There are now four instances in the literature where the LTP and 
learning and memory deficits have been rescued. 
1)  Protein replacement with a AAV-Ube3a construct ( Daily et al. 2011);  
2) Alterations in alpha CamKII at threonine 305/306 (van Woerden et al. 2007); 
3) Application of ErbB inhibitors (Kaphzan et al. 2012); 
4) Genetic decreas of α1 subunit of Na/K ATPase (a1-NaKA) (Kaphzan et al. 
2013). 
The rescue with the alpha CamKII TT305/306V a point mutation double mutant animal 
was the original report. In hindsight, and keeping in mind the LTD defect we observed, 
the rescue may be due to the presence of more active CaMKII. This would result in 
overcoming the occluded LTD and perhaps counteracting the increase in Arc. Thus, the 
CaMKII molecule is not the site of action, but rather what activated CaMKII does. In this 
case, increase AMPA insertion and make the synapse more reactive to stimulation and 
potentiation. A recent report shows that the genetic reduction of α1 NaKA through a 
double cross (Ube3a m-/p+ / α1-NaKA -/+) reversed LTP and cognitive deficits in AS 
mouse models. The mechanism of this rescue is still unknown; however, it has been 
hypothesis that the decrease in α1-NaKA expression leads to normalization of 
decreased excitability caused by excessive hyperpolarization. The alterations in intrinsic 
neuronal membrane properties (increased hyperpolarization) may result in abnormal 
threshold not only for induction of LTP but for LTD as well. These studies support the 
idea that occlusion of LTD may underlie many of phenotypes of the AS mouse model 
and may play a role in the cognitive disruption in human AS.  
Recent research has linked mGluR-LTD to a variety of disorders including 
Parkinson‘s, Alzheimer‘s, Fragile X Mental Retardation (FXS), and drug addiction 
(reviewed in Lüscher and Huber 2010). Interestingly, AS and FXS show overlapping 
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symptoms in humans and mice. Additionally, analogous disregulation of cellular 
pathways such as increase in Arc and abnormal AMPAR distribution provide additional 
evidence of molecular convergence in these diseased conditions (Niere et al. 2012). In 
Chapter 4 we attempted to elucidate the role of Ube3a in FXS pathology. We found the 
decrease in synaptic Ube3a level in the hippocampus of adult Fmr1 KO suggesting that 
some of the biochemical and behavioral phenotypes described in this mouse model 
could originate from the Ube3a deficiency. Moreover, synaptoneurosomes stimulation 
with DHPG induced Ube3a translation in wild type animals but not in Fmr1 KO samples 
support the possibility of a Ube3a mRNA and FMRP connection. However, FMRP co-
immunoprecipitation failed to detect such an interaction.  
 The analysis of Ube3a mRNA in dendrites or in the actively translated 
polyribosomes could shed more light on the FMRP and Ube3a link. While we observed a 
reduction in Ube3a, we sought to determine if the Fmr1 KO cognitive defects could be 
rescued by the addition of exogenous Ube3a via AAV9 viral vector. The behavioral 
testing revealed that increase in Ube3a negatively affected contextual fear conditioning. 
This experiment, however, harbors a few caveats. One of them is the difficulty to 
determine how much of the exogenous Ube3a is expressed from the virus in the Fmr1 
KO mice. We can easily differentiate Ube3a-AAV expression in the brain of AS mice; 
however, amount or location of Ube3a-AAV expression could not be resolved from the 
endogenous Ube3a product due to the absence of any molecular tag on Ube3a-AAV 
construct. Lastly, the detected decrease in Ube3a was synapse-specific. It is feasible to 
hypothesize that the supplementation with Ube3a could alleviate some of the symptoms 
when it is delivered specifically to the synapses and does not increase the total Ube3a 
protein through the cell mimicking ASD conditions (Nakatani et al. 2009; Smith et al. 
2011). 
121 
 
In summary, what lessons have we learned about Angelman Syndrome using 
these novel approaches? First, the contribution of Ube3a to basal and activity induced 
synaptic strength is much greater than was previously thought as it presents as a deficit 
for both LTP and LTD. Second, Ube3a likely plays roles beyond the constitutively 
expressed housekeeping protein in light of its activity-dependent alteration in response 
to neuronal activity. Third, Ube3a doesn‘t necessarily need to target a specific protein to 
be involved in altering its activity as seen in ERK phosphorylation, a kinase central to 
mechanisms involved in learning and memory. Forth, Ube3a may potentially contribute 
to different childhood neurodevelopmental disorder such as FXS emphasizing the 
significance of studying Ube3a outside the context of AS. Finally, the identification of 
major convergent pathways that underlie AS and other neurodegenerative or 
neurodevelopmental disorders may prove to be an alternative strategy for the future drug 
discoveries as it would simultaneously provide pharmacological targets for multiple 
conditions.  
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